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Abstract: Treatment options for chronic myeloid leukemia (CML) have changed dramatically 
during the last decades. Interferon-α treatment and stem cell transplantation (SCT) clearly 
improved survival over conventional chemotherapy and offered the possibility of complete and 
durable responses. With the advent of the small molecule inhibitor imatinib mesylate (Glivec®, 
GleevecTM) targeting the causative Bcr-Abl oncoprotein, the era of molecular cancer therapy 
began with remarkable success especially in chronic phase patients. Today, imatinib is the 
ﬁ  rst-line treatment for CML. However, imatinib does not appear to be capable to eliminate all 
leukemia cells in the patients and pre-existing as well as acquired resistance to the drug has been 
increasingly recognized. To overcome these problems, several strategies involving dose escala-
tion, combinations with other agents, and novel Bcr-Abl inhibitors have been developed.
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Introduction
Basic research during the past decades has resulted in considerable advances in our 
knowledge of the biology underlying neoplastic disorders. This provides the basis for 
the development of molecular targeted therapies we are witnessing today. Several new 
molecular pharmaceuticals now pave their way to clinical practice. One of the best 
examples in this context is the development of new treatment strategies for chronic 
myeloid leukemia (CML), the ﬁ  rst human malignancy which was linked to an acquired 
genetic abnormality (Nowell and Hungerford 1960; Rowley 1973). Biology, clini-
cal presentation and diagnostics of CML have been extensively reviewed elsewhere 
(Faderl et al 1999a, b; Sawyers 1999; Barnes and Melo 2002; Vardiman et al 2002; 
Cortes 2004; Hughes et al 2006). In this review we present the current knowledge on 
CML treatment with focus on imatinib. For this, we searched MEDLINE from 1960 
to May 2007 and used information obtained during the 46th, 47th, 48th annual meet-
ings of the American Society of Hematology (San Diego, December 2004, Atlanta, 
December 2005, and Orlando, December 2006), and the 43th annual meeting of the 
American Society of Clinical Oncology (Chicago, June 2007).
Cytoreductive chemotherapy
In 1953 busulfan was introduced into clinical practice. The substance rapidly became 
treatment of choice for CML based on its superiority compared to radiation therapy but 
was associated with a number of serious side effects including infertility and the risk 
of bone marrow aplasia, pulmonary, hepatic, and cardiac ﬁ  brosis (Silver et al 1999; 
Lee 2000). Subsequently, busulfan has been replaced by the less toxic Hydroxyurea 
(Hehlmann et al 1993; Chronic Myeloid Leukemia Trialists’ Collaborative Group 
1997) a substance that was introduced into clinical practice in the late 1960s and pos-
sesses a wide therapeutic window. Both chemotherapeutics provided symptomatic and 
hematologic improvement in the chronic phase and resulted in a somewhat prolonged Therapeutics and Clinical Risk Management 2008:4(1) 164
Henkes et al
survival. But none of these substances induces cytogenetic 
remissions in a signiﬁ  cant proportion of patients.
Interferon-α
Interferon-α was introduced in the 1980s (Talpaz et al 1983, 
1986). In contrast to conventional cytoreductive chemo-
therapies Interferon-α was capable of inducing complete 
cytogenetic remissions in varying frequencies up to 26% 
in chronic phase patients (Silver et al 1999) and extending 
survival (Hehlmann et al 1994; Chronic Myeloid Leukemia 
Trialists’ Collaborative Group 1997). Interferon-α was the 
ﬁ  rst pharmacological treatment that signiﬁ  cantly affected 
the diseases natural course. The latest updates of the major 
Interferon-α studies reported a 9-year or 10-year overall 
survival ranging from 27%–53% (Baccarani et al 2003). 
Major cytogenetic remissions (<35% Ph+ metaphases) were 
associated with prolonged survival although most patients 
remain bcr-abl PCR positive if sensitive techniques are used 
(Hochhaus et al 1995, 1996, 2000). Patients that achieve a 
complete cytogenetic remission are likely to do very well 
and long term survivors are observed within this group of 
patients (Hehlmann et al 1994; The Benelux CML Study 
Group 1998; Bonifazi et al 2001).
However, side-effects limit the clinical utility of Interferon-α. 
These include fatigue, myalgias, arthralgias, headaches, weight 
loss, depression, diarrhea, neurological symptoms, memory 
changes, hair thinning, autoimmune diseases, and cardiomy-
opathy (Talpaz et al 1991; Sacchi et al 1995; Wetzler et al 
1995; O’Brien et al 1996). Efforts to further improve results 
of Interferon-α included the retrieval for optimized dosing 
(Kluin-Nelemans et al 2004), the evaluation of pegylated 
Interferon-α (Michallet et al 2004), and the combination with 
other substances like Cytarabine (Guilhot et al 1997; Kantarjian 
et al 1999; Silver et al 2003; Kuhr et al 2003).
Allogeneic stem cell transplantation
Until now allogeneic stem cell transplantation (SCT) is the 
treatment modality proven to cure more CML patients than all 
other treatment options. However, the utility of SCT is ham-
pered by side-effects including immunodeﬁ  ciency, infections, 
organ toxicity from the conditioning regiment, and acute as 
well as chronic graft versus host disease leading to signiﬁ  cant 
treatment related mortality. The longest follow-up of patients 
who received matched sibling SCT has been reported by 
the European Group for Blood and Marrow Transplantation 
(EBMT) on 2628 patients treated between 1980 and 1990 
(Gratwohl et al 2006). Overall survival at 20 years was 34% 
for all patients, 38% for patients who received transplants in 
ﬁ  rst CR and 49% for those who had an EBMT risk score of 
0–1. Several prognostic factors in CML patients receiving allo-
geneic SCT had been described, including age, interval from 
diagnose to HSCT, disease phase, donor-recipient sex match, 
and donor type (Gratwohl et al 1998; Passweg et al 2004).
The efﬁ  cacy of allogeneic SCT for treatment of CML is 
largely related to alloimmune effects, as demonstrated by the 
excellent results of donor lymphocyte infusions (DLI) in case 
of post transplant relapse (Guglielmi et al 2002).
The best results from SCT have been obtained when 
the procedure was accomplished early in the disease course 
in young patients lacking signiﬁ  cant co-morbidities with a 
suitable HLA-matched donor. Hence, young patients with 
high-risk CML and an optimal stem cell donor may have the 
greatest beneﬁ  t from an early transplant.
Prior to the introduction of tyrosine kinase inhibitors into 
clinical practice, chronic phase was the most common single 
indication for allogeneic SCT. The considerable reduction 
in the numbers of transplants reported to the EBMT and the 
IBMTR since 1998/99 reﬂ  ected efﬁ  cacy, excellent duration 
of remissions, tolerability, and increased use of tyrosine 
kinase inhibitors in these patients (Gratwohl et al 2004; 
Giralt et al 2007). This resulted in the recommendation to 
treat all newly diagnosed adult patients with imatinib unless 
exceptional circumstances prevail (Baccarani et al 2006). 
Consequently, despite several improvements in the ﬁ  eld of 
allogeneic SCT, its place is now as a salvage strategy for 
patients failing on imatinib therapy. In addition, with the 
advent of second-generation tyrosine kinase inhibitors such 
as dasatinib and nilotinib, the use of allogeneic SCT may be 
delayed further in the course of a patient’s disease. In this 
regard superior estimated 2-year survival rates reported for 
subsequent treatment with nilotinib or dasatinib compared to 
allogeneic SCT in chronic phase but not in accelerated phase 
or blast crisis CML post-imatinib failure (Kantarjian et al 
2007b) are interesting. However, valid long term survival 
comparisons between allogeneic SCT and non-transplant 
second line treatment approaches post-imatinib failure are 
not available at the moment.
The role of SCT as second- or third-line treatment in 
chronic phase CML is further assisted by the recently published 
results of the German CML III study. Herein 354 previously 
stratiﬁ  ed adult patients with chronic phase CML eligible for 
allogeneic SCT were included. 135 patients had a matched 
sibling donor of which 91% received a transplant within a 
median of 10 months from diagnosis. 219 patients had no 
donor and received conventional drug treatment. With a 
median observation time of 8.9 years survival was signiﬁ  cantly Therapeutics and Clinical Risk Management 2008:4(1) 165
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superior for the conventional drug treatment, superiority being 
most pronounced in low risk patients. Although Interferon-α 
was used as primary conventional treatment in this trial, the 
main results are valid and relevant in the imatinib era, as the 
majority of patients switched to imatinib during the observation 
period of the study (Hehlmann et al 2007).
The decision to proceed to allogeneic SCT has to be 
based on a balance of risks. CML disease risk scores (Sokal 
et al 1984; Hasford et al 1998) and transplant associated risk 
scores for CML patients (Gratwohl et al 1998; Passweg et al 
2004) provided assistance to this decision. However, patients 
included in historical analyses on which these scores are 
based were treated over a decade ago. With the improvements 
in HLA-matching, patient selection and supportive care, 
transplant outcomes are better today and specialized cent-
ers have shown nearly comparable results with related and 
unrelated donor transplants, especially in low risk patients 
(Weisdorf et al 2002) with a 3-year overall survival rate of 
86% in matched related donor SCT for chronic phase CML 
(Radich et al 2003). The EBMT reported an improvement of 
the 2-year survival from 53% to 61% in the most recent years 
due to a reduction in transplant-related mortality from 41% to 
30% in all patients and from 31% to 17% in low-risk patients 
(Gratwohl et al 2006). Outcome improvement of allogeneic 
SCT during the last decade is pronounced in patients with a 
low (0–1) risk score, where overall survival has increased to 
80% in the more recent transplants. Unfortunately, improve-
ments for patients in accelerated phase and blast crisis have 
been smaller (Gratwohl et al 2006).
Because SCT is mostly used as a salvage treatment after 
imatinib failure, the impact of imatinib treatment prior to 
allogenic SCT was of great interest. Imatinib treatment 
preceding allogeneic SCT neither increased transplantation-
related morbidity nor mortality (Shimoni et al 2003; Kim et al 
2004; Zaucha et al 2005; Bornhäuser et al 2006; Deininger 
et al 2006; Stylian et al 2006; Oehler et al 2007; Weisser et al 
2007). Additionally, imatinib was found to control leukemia 
in patients relapsing after allogeneic transplant (Kantarjian 
et al 2002c; Olavarria et al 2003; DeAngelo et al 2004) and 
has also been studied as additional treatment early after allo-
geneic SCT in high risk Philadelphia chromosome positive 
leukemias (Carpenter et al 2007).
Imatinib mesylate (Glivec®/GleevecTM)
Development and early trials
Improvements in the understanding of the molecular mecha-
nism underlying CML has led to the evolution of targeted 
therapies. In the early 1990s, Lyndon and Matter worked 
on the development of speciﬁ  c tyrosine kinase inhibitors. 
From this drug discovery program, imatinib was generated. 
Imatinib is a 2-phenylaminopyrimidin derivate (Figure 1) 
and was initially developed as a speciﬁ  c platelet-derived 
growth factor receptor (PDGFR) inhibitor, but was later 
found to inhibit autophosphorylation of Abl and c-Kit. The 
substance showed promising in vitro and in vivo activity in 
Bcr-Abl positive CML and ALL cell lines (Druker et al 1996; 
Buchdunger et al 1996). Imatinib binds to the ATP binding 
pocket and stabilizes the inactive form of the Abl kinase 
(Figure 3, left panel) (Schindler et al 2000). It functions as a 
competitive inhibitor of the Bcr-Abl tyrosine kinase leading 
to inhibition of proliferation, restoration of cell cycle control, 
induction of apoptosis and reversal of genetic instability in 
Bcr-Abl dependent cells in vitro (Gambacorti-Passerini et al 
1997; Oetzel et al 2000; Jonuleit et al 1998; Jonuleit et al 
2000; van der Kuip et al 2004).
Eighty-three CML patients who failed on Interferon-α 
treatment or who could not tolerate the drug, were enrolled 
in the ﬁ  rst phase I trial with imatinib. Imatinib doses of 
25–1000 mg per day were evaluated. Dose limiting toxicity 
was not encountered, although at imatinib dosages above 
750 mg per day a higher frequency of severe toxicities 
occurred. Notably, complete hematological remissions were 
reported in 53 of 54 patients receiving an imatinib dose of 
300 mg or more per day and 31% of these patients achieved 
a major cytogenetic remission. Hematological responses 
usually occurred within the ﬁ  rst month of treatment, whereas 
cytogenetic responses generally required at least 3 months 
of treatment (Druker et al 2001). Subsequently, open-label 
single-arm phase II trials were conducted in three different 
groups of CML patients, namely chronic phase after 
Interferon-α failure, accelerated phase, and blast crisis. 
Imatinib was administered orally once daily and initially 
all patients received 400 mg per day. Early in these trials, 
however, the imatinib dose was increased to 600 mg per day 
for patients with accelerated phase and with blast crisis and 
patients with resistant or progressive disease could receive 
doses up to 800 mg per day (administered as 400 mg twice 
daily). The excellent efﬁ  cacy results of these phase II trials 
are summarized in Table 1. Overall these trials also afﬁ  rmed 
the acceptable toxicity proﬁ  le of imatinib. These data clearly 
supported the accelerated FDA approval of the substance for 
the treatment of advanced CML (in accelerated or blastic 
phase or in chronic phase after Interferon-α failure) in the 
year 2001, followed by the approval as ﬁ  rst-line treatment for 
chronic phase CML in the year 2002 (Cohen et al 2002).Therapeutics and Clinical Risk Management 2008:4(1) 166
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Figure 1 Molecular structures of imatinib, nilotinib, dasatinib, and ON012380.   The respective H-bond interactions with the Abl kinase domain are indicated in red.  Derived 
from Weisberg et al (2006).Therapeutics and Clinical Risk Management 2008:4(1) 167
Imatinib for chronic myeloid leukemia
Results in chronic phase CML
The high complete cytogenetic remission rates, ranging from 
41% to 64% with a 5-year progression-free survival of 
69% and a 4-year overall survival of 86%–88% in different 
international trials with imatinib treatment in chronic phase 
CML patients resistant or intolerant to interferon-α  further 
emphasized its exceptional potency (Kantarjian et al 2002a, b; 
Cervantes et al 2003; Kantarjian et al 2004a; Rosti et al 2004; 
Gambacorti et al 2005). The superiority of 400 mg imatinib 
daily over interferon-α combined with low dose cytarabine 
as ﬁ  rst-line treatment in chronic phase CML was established 
in the International Randomized Study of Interferon and 
STI571 (IRIS), which included 1106 adult patients. The 
highly signiﬁ  cant superiority after a median follow-up of 19 
months with a complete hematological response rate of 95% 
versus 55%, a complete cytogenetic response rate of 76% 
versus 15%, an estimated one year 3 log reduction rate of 
the bcr-abl transcript in 39% versus 2%, and a survival free 
from progression to accelerated phase or blast crisis of 97% 
versus 91% (p   0.001) profoundly changed CML treatment. 
Beside its surpassing efﬁ  cacy the substance resulted in a clearly 
improved treatment compliance, quality of live and freedom 
from toxicity due to its lower rate of side-effects (O’Brien 
et al 2003; Hughes et al 2003). After a median follow-up of 
60 months estimates of cumulative best rates of complete 
cytogenetic response among patients receiving imatinib in the 
IRIS trial were 87%, indicating that additional patients reach 
a complete cytogenetic response after more than 12-month of 
treatment. The estimated annual rate of treatment failure after 
the start of imatinib therapy was 3.3% in the ﬁ  rst year, 7.5% in 
the second year, 4.8% in the third year, 1.5% in the fourth year, 
and 0.9% in the ﬁ  fth year. The corresponding annual rates of 
progression to the accelerated phase or blast crisis were 1.5%, 
2.8%, 1.6%, 0.9%, and 0.6%, respectively. This decrease in 
the proportion failing annually to imatinib treatment further 
supported that imatinib has to be regarded as standard of care 
ﬁ  rst line treatment of CML (Druker et al 2006).
The 5-year overall survival rate of 89% for patients who 
received imatinib as initial therapy within the IRIS trial is higher 
than that reported in any previously published prospective 
CML trial. The IRIS trial allowed patients to cross over to the 
alternative treatment, and most patients in the Interferon arm 
either switched to imatinib or discontinued Interferon. Therefore, 
the intention-to-treat analysis found no signiﬁ  cant difference 
in overall survival between the two study groups (Druker 
et al 2006). Randomized trials of interferon-α plus cytarabine, 
performed before the availability of imatinib, showed a 5-year 
overall survival of 68%–70% (Guilhot et al 1997; Baccarani et al 
2002). As it seems unethical to withhold imatinib for patients 
failing on Interferon, such historical comparisons are the only 
way to study the impact of imatinib on survival. However, the 
magnitude of the survival advantage for therapy with imatinib 
over Interferon-α based therapies provides sufﬁ  cient evidence 
for the superiority of this new drug (Roy et al 2006).
Despite the clinical use of imatinib for 9 years dose issues are 
not yet completely settled. The maximum tolerated dose was not 
identiﬁ  ed in the early trials (Druker et al 2001). At 400 mg per 
day the blood concentration of imatinib was consistently higher 
than that required for 50% Bcr-Abl tyrosine kinase activity in 
vitro (Peng et al 2004; Schmidli et al 2005). 600 mg per day 
was likely to be more effective in accelerated and blastic phase 
CML and increasing the dose up to 800 mg per day can beneﬁ  t 
a subgroup with either an inadequate cytogenetic response or 
disease progression (Kantarjian et al 2003a; Zonder et al 2003). 
Additionally, there is evidence that high dose imatinib (800 mg 
per day) results in superior response rate and progression free 
survival in patients with untreated early chronic phase CML 
than standard dose treatment (Aoki et al 2006).
Trials using high dose imatinib (Cortes et al 2003; Hughes 
et al 2004, 2005; Kantarjian et al 2004b) have not compared 
this approach with the standard dose of 400 mg on a random-
ized basis, thus the role of higher versus standard dose imatinib 
in the ﬁ  rst-line treatment of chronic phase CML remains to be 
determined in the ongoing trials. However, from the pharma-
cologic point of view the simple one-dose-ﬁ  ts-it-all approach 
might not be optimal. Interestingly, mean through imatinib 
plasma levels were signiﬁ  cantly higher in an imatinib treated 
group of patients with complete cytogenetic response than in 
the group without and higher in the group with major molecular 
response than in the group without (Picard et al 2007).
Results in accelerated phase 
and blast crisis
In patients with accelerated phase CML a daily dose of
600 mg resulted in a complete hematological response rate 
Table 1 Efﬁ  cacy of imatinib in early phase II trials
 CML-CP,  IFN    CML-AP  CML-BC
 failure   
Hematological 88% 63%  26%
response
Major cytogenetic  49%  21%  13.5%
response
Complete cytogenetic  30%  14%  5%
response
Adapted with permission from Cohen et al (2002).
Abbreviations: CML-CP, CML in chronic phase; IFN, interferon; CML-AP, CML in 
accelerated phase; CML-BC, CML in blast crisis.Therapeutics and Clinical Risk Management 2008:4(1) 168
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of 37%, a complete cytogenetic response rate of 19%, and a 
3-year progression free survival of 40% (Talpaz et al 2002; 
Silver et al 2004). 25% of patients with blast crisis CML treated 
with imatinib achieved a complete hematological remission, but 
progression free survival was rather short, with a median of 10 
months or less and only about 7% remaining progression free 
after 3 years (Sawyers et al 2002; Silver et al 2004). Clearly, 
long-term results with imatinib in these advanced CML stages 
are less impressive than in the chronic phase. Allogeneic SCT 
can cure a signiﬁ  cant proportion of advanced stage CML 
patients but it is toxic and can not be offered to every affected 
patient. Deﬁ  nitely, further improvements in accelerated and 
blastic phase of CML are desperately needed.
Pharmacokinetics
Bioavailability of imatinib in healthy volunteers is 92% 
(86%–99%) with a mean plasma terminal half-live of 13.5 
(±0.9) hours for imatinib and 20.6 (±1.7) hours for the phar-
macologically active N-desmethyl metabolite (CGP74588) 
(Gschwind et al 2005). In a patient with short bowel syndrome, 
an 80% decrease in imatinib plasma level due to impaired 
absorption has been demonstrated (Beumer et al 2006). This 
indicates the importance of considering gastrointestinal ana-
tomic abnormalities or disorders when imatinib is dosed. Ima-
tinib is approximately 95% bound to human plasma proteins, 
mainly albumin and α1-acid glycoprotein (A1AGP). The drug 
is eliminated predominantly via the bile in form of metabolites, 
one of them (CGP74588) shows comparable pharmacological 
activity to the parent drug. The fecal to urinary excretion ratio is 
approximately 5:1 (Peng et al 2005). Cytochrome P-450 (CYP) 
enzymes reduce or alter the pharmacologic activity of many 
drugs and facilitate their elimination (Wilkinson 2005). Imatinib 
is metabolized mainly by CYP3A4 or CYP3A5 and can com-
petitively inhibit the metabolism of drugs that are CYP3A4 or 
CYP3A5 substrates. Interactions may occur between imatinib 
and inhibitors or inducers of these enzymes, leading to changes
in the plasma concentration of imatinib as well as co-administered 
drugs (Peng et al 2005). Hepatic and renal dysfunction may 
result in more variable and increased exposure to imatinib, 
although typically not necessitating dosage adjustment 
(Peng et al 2005). Currently monitoring imatinib plasma
levels is not routinely performed. However, growing evidence 
suggests that maintaining adequate plasma levels correlates 
with best responses (Larson et al 2006; Picard et al 2007).
Toxicity and adverse events
The exceptional efﬁ  cacy and tolerable toxicity proﬁ  le of 
imatinib was the reason for an FDA approval after a relatively 
short follow-up. Meanwhile, a longer follow-up has revealed 
some additional toxicities which were initially not reported. 
Although, imatinib remains a generally well tolerated drug, 
some of its toxicities need to be mentioned and carefully 
monitored for they sometimes demand especial measures by 
the clinician. Second generation tyrosine kinase inhibitors 
now provide an opportunity to overcome imatinib-induced 
toxicities in some of the patients.
Hematological cytopenias
Myelosuppression is particularly common in CML patients 
treated with imatinib and it is more pronounced in patients 
with advanced disease. Myelosuppression can occur at any 
time during imatinib therapy, but it usually starts within the 
ﬁ  rst weeks of treatment. In the IRIS trial grade 3 neutropenia 
was experienced by 11% of patients and grade 4 neutrope-
nia occurred in 2% of patients. Grade 3 thrombocytopenia 
occurred in 6.9% of patients, and grade 4 thrombocytopenia 
in less than 1% of patients (Hughes et al 2003; O’Brien 
et al 2003). It was mandatory in the protocol to interrupt 
therapy with imatinib for grade 3 or 4 myelosuppression in 
chronic phase CML patients. This did not apply to patients 
with accelerated phase and blast crisis with grade 3 or 4 
myelosuppression, because of the life-threatening nature of 
the disease. Thus, using these guidelines myelosuppression 
was more common in trials with BC- or AP-CML (AP-CML: 
neutropenia grade 3/4: 23/35% and thrombocytopenia grade 
3/4: 31/12%, BC-CML: neutropenia grade 3/4: 16/48% and 
thrombocytopenia grade 3/4: 29/33%) (Sawyers et al 2002; 
Talpaz et al 2002).
Hematopoiesis in CML patients is mainly derived from 
Ph-positive stem cells and with disease progression the 
progenitor cell compartment gradually becomes dominated 
by the Ph-positive clone (Petzer et al 1996). Therefore, 
myelosuppression may reﬂ  ect rather delayed recovery of the 
normal hematopoietic cell compartment than the toxicity on 
hematopoietic cells. Accordingly, in vitro and in vivo data 
indicate that imatinib does not severely affect normal hema-
topoiesis (Druker et al 1996; Deininger et al 1997). Further 
evidence that imatinib does not signiﬁ  cantly suppress normal 
hematopoiesis results from the recovery of normal blood 
counts in patients with advanced-phase CML during con-
tinuous therapy with imatinib. These observations indicate 
that myelosuppression induced by imatinib is much more a 
consequence of the therapeutic effect on the leukemic clone 
than an inhibitory effect on the normal hematopoiesis.
Details in the management of imatinib-induced side 
effects have been reviewed elsewhere (Deininger et al 2003). Therapeutics and Clinical Risk Management 2008:4(1) 169
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In brief, the aggressiveness of therapy has to be balanced 
against the risk of progression of the disease. Dose reductions 
below 300 mg per day are unlikely to assist in the recovery of 
normal hematopoiesis but may allow emergence of imatinib-
resistant leukemic clones. To manage myelosuppression 
of grade 3 to 4 G-CSF is an option (Marin et al 2003). 
Temporary interruption of treatment is preferred to dose 
reduction in chronic phase CML (Deininger et al 2003). In 
patients with advanced-phase disease, it is unclear whether 
the best option is to continue therapy with imatinib in the face 
of severe myelosuppression and to manage complications 
aggressively (as is standard practice in the management of 
acute leukemia) or alternatively, to act as with patients in 
chronic phase. A published approach in that situation has 
been to not interrupt therapy or reduce doses on the basis of 
thrombocytopenia, but to appropriately support these patients 
with platelet transfusions. In case of clinically signiﬁ  cant 
bleeding, imatinib has to be stopped immediately until the 
bleeding is controlled. Furthermore, bone marrow should 
be examined for cellularity and residual leukemia when 
absolute neutrophile counts (ANC) drop below 500/mm3 
(Deininger et al 2003). In patients whose marrow remains 
hypercellular or with blasts greater than 30%, imatinib 
should be continued. If the marrow is hypocellular and the 
ANC is less than 500/mm3 for 2–4 weeks a reduction of the 
imatinib dose, the temporary interruption of treatment or the 
use of myeloid growth factors for approximately 2 weeks are 
generally practicable options (Deininger et al 2003).
Nonhematological toxicities
The most common nonhematologic side effects in phase II 
and III trials were nausea, muscle cramps, ﬂ  uid retention, 
diarrhea, musculoskeletal pain, fatigue, and skin rashes. 
Only few patients experienced nonhematologic grade 3–4 
toxicity. The incidence of some speciﬁ  c side-effects was dif-
ferent according to the stage of CML. For example, vomiting 
and ﬂ  uid retention were more prevalent in advanced-phase 
disease, whereas musculoskeletal symptoms and weight gain 
were more common in the chronic phase (Cohen et al 2002; 
Deininger et al 2003). In the meantime, longer follow-up has 
revealed some additional nonhematological toxicities which 
were initially not reported.
Gastrointestinal side-effects
Nausea and occasionally vomiting are toxicities frequently 
seen with imatinib. These side-effects are usually dose-
related and mild. They can be avoided in most patients when 
imatinib is taken with food, which does not alter the drugs 
pharmacokinetics. Patients with a history of esophagitis or 
hiatal hernia are advised to take the drug at least 2 hours 
before bedtime and 800 mg doses should be taken as 400 mg 
bid with two separate meals to avoid local irritant effects on 
the esophageal and the gastric mucosa. If nausea cannot be 
adequately controlled by such simple measures administra-
tion of antiemetics (eg, metoclopramide or ondansetrone) 
can provide better relief to the patients.
Diarrhea is another relatively common dose-related side-
effect of imatinib. It is possible that diarrhea is caused by 
local irritant effects. Alternatively, the inhibition of c-Kit, 
which is highly expressed in the interstitial pace maker cells 
of Cajal, has been discussed (Deininger et al 2003; Popescu 
et al 2006). Diarrhea can easily be managed by antidiarrheal 
co-medications in most of the symptomatic patients.
Fluid retention and cardiotoxicity
Mild ﬂ  uid retention and edema (often in the periorbital 
region) are other common dose-related toxicities of imatinib, 
occurring in about 50%–70% of the patients (Cohen et al 2002). 
For periorbital edema no speciﬁ  c therapy is required in most 
of the cases. Serious generalized ﬂ  uid retention is a much 
less common but a potentially life-threatening events which 
has been reported in less than 1% of chronic phase, but in 
3% and 6% of patients in accelerated phase and blast crisis, 
respectively (Cohen et al 2002). It can present as pulmonary 
edema, pleural or pericardial effusion, ascites, anasarca, joint 
effusion, and cerebral edema. Live threatening events have 
been attributed to this ﬂ  uid retention syndrome and one death 
occurred from cerebral edema (Ebnoether et al 2002). The 
underlying mechanism in such generalized imatinib-induced 
ﬂ  uid retention and edema may be not consistent. One pos-
sible explanation could be the inhibition of targets that are 
responsible for the integrity of capillaries by imatinib. Mice 
with homozygous deletions of PDGF-B or PDGFR-β genes 
have defective blood vessels and edema (Lindahl et al 1997) 
and abl/arg double knockout mice also have edema (Koleske 
et al 1998), suggesting such a role for these tyrosine kinases. 
Additionally, a monoclonal anti-PDGFRβ antibody (CDP 
860) used as anti-cancer agent in an early phase clinical 
trial in 8 cancer patients resulted in ﬂ  uid retention in 7 cases 
(Jayson et al 2005).
Another mechanism which may be the cause of ﬂ  uid 
retention in some patients is the development of severe 
congestive heart failure (CHF), possibly due to a Abl related 
toxic cardiomyopathy, that was just recently described 
(Kerkela et al 2006). However, evidence of the clinical 
signiﬁ  cance of imatinib-induced cardiotoxicity is still small. Therapeutics and Clinical Risk Management 2008:4(1) 170
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There is a need for further studies to evaluate cardiotoxicity 
in patients receiving the substance, taking into account dose 
levels of the drug, pre-existing cardiac conditions, and the 
use of additional cardiotoxic drugs (Schellings et al 2007). 
For this, Atallah et al reviewed all serious adverse events 
reported during various imatinib trials (Atallah et al 2007a). 
Among 1276 CML patients treated with imatinib, 22 patients 
(1.7%) were identiﬁ  ed as having CHF by the Framingham 
criteria. Patients who developed CHF were signiﬁ  cantly 
older compared with patients who did not develop such 
symptoms and 82% of the patients with CHF had previous 
medical conditions predisposing to cardiac disease. This 
reconﬁ  rmed some of the previously recognized risk factors 
for imatinib-induced ﬂ  uid retention (female sex, age over 65, 
and a history of cardiac or renal insufﬁ  ciency) (Deininger 
et al 2003). Indeed, the incidence of CHF per age group was 
nearly identical to that reported for the general population 
in the Framingham study (Atallah et al 2007a). Half of the 
patients who developed CHF continued imatinib therapy with 
dose adjustments and management for their CHF-symptoms 
with no further complications (Atallah et al 2007a).
Thus, patients should be monitored closely for the presence 
of peripheral edema, rapid weight gain and other clinical 
signs of possible cardiac dysfunction. However, routine 
echocardiographic monitoring in otherwise asymptomatic 
patients treated with imatinib does not appear to be indicated. 
Cardiologic counseling and appropriate supportive measures 
(eg, salt-restriction, diuretics, ACE-inhibitors, beta blockers) 
should be initiated as soon as evidence for cardiac dysfunction 
occurs. In patients with severe ﬂ  uid retention or cardiac 
dysfunction, imatinib has to be discontinued until the 
situation is adequately controlled with supportive measures 
(Deininger et al 2003). The decision whether imatinib 
should be reinitiated depends on the patients’ disease risk 
and the availability of alternative treatment options. In cases 
with signiﬁ  cant ﬂ  uid retention not associated with cardiac 
dysfunction supportive treatment approaches also comprise 
salt restriction and diuretics as ﬁ  rst line options. In very severe 
cases and in cases not responding to the ﬁ  rst-line measures 
imatinib should be interrupted and sometimes glucocorticoids 
or occasionally thoracocentesis or pleurodesis might become 
necessary.
Teratogenic and embryotoxic side-effects
Tyrosine kinases are critical signaling molecules for the 
cellular regulation of proliferation, differentiation, survival, 
function, and motility. Due to their fundamental role in cell 
biology possible adverse effects by a more or less speciﬁ  c 
inhibition of tyrosine kinases in pregnancy and early infancy 
could be expected. The importance of Abl for a proper 
embryonic development is underscored by the phenotype 
of abl knock out mice. These animals display increased 
perinatal mortality, runtedness, abnormal spleen, head, and 
eye development, and dysfunctions of the immune system 
(Schwartzberg et al 1991). Imatinib can be excreted with 
breast milk and preclinical data demonstrated the teratogenic 
and embryotoxic potential of the substance. Consequently, 
imatinib was not approved in breast feeding and pregnant 
women. Sexually active women in childbearing age that 
have to be treated with imatinib are advised to carefully 
exert contraception. Despite this advise, several pregnancies 
developed in women treated with imatinib during the last 
years with different outcomes being reported (Ali et al 2004; 
Ault et al 2006; Prabhash et al 2005; Choudhary et al 2006; 
Suppiah and Kalaycio 2006). A study on 180 pregnancies in 
women exposed to imatinib was recently presented (Pye et al 
2006). Outcome data were shown for 125/180 (69%) cases. 
63 pregnancies resulted in the birth of normal live infants. 
Thirty-ﬁ  ve women underwent elective terminations, 3 fol-
lowing identiﬁ  cation of fetal defects. The remaining group 
either had no defects or was of unknown status. There were 
12 pregnancies with fetal abnormalities, resulting in 8 live 
and 1 still birth and 18 pregnancies ended in spontaneous 
abortion. Fetal abnormalities included among others several 
bony defects and cases with an exomphalos. Similar bony 
defects including exencephaly, encephaloceles and defor-
mities of the skull bones had been described previously in 
animal models. Despite this, balancing the risk to the fetus of 
continuing imatinib against the risk to the mother of stopping 
treatment remains complex. Decisions have to be made on 
an individual basis after careful counseling of both parents 
(Pye et al 2006).
Male fertility is obviously preserved in at least some 
patients treated with imatinib. However, oligospermia and 
reduced sperm motility has been observed in animals and 
humans treated with imatinib (Seymour et al 2006). Clearly, 
one possibility for men desiring conception is the sperm 
cryopreservation before starting imatinib treatment.
Musculoskeletal and metabolic side-effects
Painful musculoskeletal complaints are another common 
side-effect of imatinib. Muscle cramps occur mainly in the 
hands, feet, calves, and thighs. Despite the fact that ionized 
calcium and magnesium levels are usually normal in patients 
treated with imatinib, calcium and magnesium supplements, 
as well as quinine, can offer symptomatic relief to these Therapeutics and Clinical Risk Management 2008:4(1) 171
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cramps (Deininger et al 2003) and the therapeutic effect of 
a chlordiazepoxide has recently been shown (Medeiros and 
Lipton 2006). The cause of this adverse effect is unclear. In 
some patients these symptoms coincide with clearance of 
leukemic cells from the bone marrow.
Hypophosphatemia and associated changes in bone and 
mineral metabolism have also recently been reported. These 
alterations appear to be dosage and age-dependent (Berman 
et al 2006; Joensuu and Reichardt 2006; Owen et al 2006). 
Serum phosphate levels were routinely measured in two 
clinical trials, including 403 patients. Hypophosphatemia of 
Common Toxicity Criteria grade 2 or higher was observed 
in 50% (33% had grade 2, 15% grade 3, and 1.5% grade 4) 
(Owen et al 2006). Chronic, untreated hypophosphatemia can 
result in impaired bone mineralization, rickets or osteoma-
lacia. Therefore, it was advised to routinely monitor serum 
phosphate during imatinib therapy so that prompt phosphate 
replacement can be initiated (Owen et al 2006).
It was speculated, that imatinib negatively affects the 
formation and resorption of bone by inhibiting the PDGFR 
(Berman et al 2006). Prospective studies on calcium and bone 
metabolism demonstrated that altered bone remodeling and 
secondary hyperparathyroidism occurs early after the initia-
tion of imatinib (Grey et al 2006). The most parsimonious 
explanation for these ﬁ  ndings is that imatinib directly stimu-
lates bone formation while restraining resorption (Dewar 
et al 2006). This effect might be explained by inhibition of 
macrophage-colony-stimulating factor (M-CSF) receptor 
c-fms, which is essential for osteoclast formation (Dewar 
et al 2006). An alternative explanation is that imatinib both 
inhibits the intestinal absorption of calcium (which induces 
secondary hyperparathyroidism) and the bone resorption 
(which abrogates the expected increase in this measure 
induced by parathyroid hormone). Both potential mecha-
nisms involve direct skeletal effects of imatinib suggesting 
a role for imatinib -sensitive kinases in skeletal homeostasis 
in vivo (Grey et al 2006).
Imatinib might affect glucose homeostasis resulting 
in a reduced necessity for anti-diabetic treatment in some 
diabetic patients and hypoglycemia might be exacerbated in 
patients with gastrointestinal stromal tumors (GIST) exhib-
iting symptoms of non-islet cell-induced hypoglycemia. 
Physicians and patients should be aware of this potential 
adverse effect to carry out appropriate monitoring and 
adjustment of anti-diabetic treatment (Breccia et al 2004; 
Hamberg et al 2006).
Imatinib might also increase Levothyroxine replacement 
requirements in some hypothyroid patients, thus thyroid 
hormones should be additionally monitored after starting 
imatinib treatment in these patients (de Grot et al 2005, 
2006).
Cutaneous side-effects
Various imatinib-induced dermatologic side-effects have 
occurred including dermatitis, pigmentation anomalies, Sweet 
syndrome, pityriasis rosea-like eruptions, lichenoid reactions, 
erythema multiforme, acute generalized xanthematous 
pustulosis, and Stevens-Johnson Syndrome (Hsiao et al 
2002; Rule et al 2002; Vidal et al 2002; Deininger et al 2003; 
Sanchez-Gonzalez et al 2003; Pavithran and Thomas 2005; 
Kuwano et al 2006; Martin et al 2006) and have been 
reviewed recently (Robert et al 2005; Scheinfeld 2006). In 
face of the clinical heterogeneity of the imatinib-induced 
cutaneous toxicities different pathomechanisms including 
direct toxic effects as well as hypersensitivity reactions are 
likely. Most skin reactions are mild and occur within the 
ﬁ  rst 3 months of imatinib exposition. These cases often can 
easily be managed with antihistamines or topical steroids, but 
patients have to be followed closely. In more severe cases a 
short course of oral steroids can be used for treatment and 
imatinib should be interrupted temporarily. Severe cutaneous 
toxicities with desquamation are rare, but have been noticed 
in the context of imatinib treatment (Sanchez-Gonzalez et al 
2003) including reports of Stevens-Johnson syndrome (Hsiao 
et al 2002; Rule et al 2002; Vidal et al 2002; Pavithran and 
Thomas 2005). In such cases, immediate discontinuation of 
imatinib and appropriate supportive care, including systemic 
steroids (eg, Prednisone at an initial dose of 1 mg/kg) are 
indicated. Depending on the clinical situation, it has been 
possible to restart imatinib after the rash has resolved. In 
such cases, Prednisone has typically been given at 1 mg/kg 
per day, tapering to 20 mg per day over several weeks and 
imatinib has been restarted at 100 mg per day and the dose 
increased by about 100 mg per week while tapering the 
steroids, assuming that the rash has not recurred (Deininger 
et al 2003). Nowadays for patients who had a severe skin 
reaction (eg, Stevens-Johnson syndrome) alternative 
treatment options should be considered ﬁ  rst before restarting 
on imatinib.
Hepatotoxicity
Imatinib-induced hepatotoxicity turned out to be less 
problematic than predicted from animal studies. However, 
different liver function test (LFT) abnormalities have been 
observed with imatinib, typical with an increase of transami-
nases, although increases in bilirubin have also been reported. Therapeutics and Clinical Risk Management 2008:4(1) 172
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In general, grade 3 or 4 elevations in LFT are relatively 
rare. They have predominantly occurred in patients with 
advanced-phase disease in whom leukemic inﬁ  ltration of the 
liver is a possible confounding factor (Deininger et al 2003). 
Rarely fatal cases of hepatic toxicity have been reported in 
patients treated with imatinib. One occurred in a patient in 
accelerated phase after prior bone marrow transplantation 
medicated with 600 mg imatinib and 3–3.5 g acetaminophen 
per day (Talpaz et al 2002; Cohen et al 2002). Whether this 
death was causally related to the combination of imatinib and 
acetaminophen is not known. Many other patients have taken 
these two drugs in combination safely. Nevertheless, caution 
is recommended and patients should be advised about the 
possible risk of taking imatinib together with higher doses 
of acetaminophen (Deininger et al 2003). The second cause 
of fatal liver failure was reported in a 61-year-old woman 
with polycythemia vera in spent phase/myeloﬁ  brosis who 
was included into a phase II trial evaluating the efﬁ  cacy of 
imatinib in Bcr-Abl-negative myeloproliferative disorders 
(Lin et al 2003). Another patient was recently reported who 
died 3 days after liver transplant for the treatment of imatinib 
induced acute liver failure (Cross et al 2006).
Liver toxicity usually appears during the ﬁ  rst few months 
of therapy but can also occur at later time points. The patho-
genic mechanisms may not be homogenous and remain to be 
elucidated, though it appears to be a drug-induced inﬂ  am-
matory reaction on liver biopsies in some cases (Ohyashiki 
et al 2002; Ferrero et al 2006; Al Sobhi et al 2007; Dhalluin-
Venier et al 2006).
Regarding hepatoxicity, monitoring of LFT should be 
performed routinely before imatinib treatment is started, 
every other week during the ﬁ  rst month of therapy, and at 
least monthly thereafter (Deininger et al 2003). A practi-
cal approach to the management of imatinib-associated 
hepatotoxicity has been described in detail (Deininger et al 
2003) and the interruption of imatinib in cases with grade 
3–4 hepatotoxicity clearly is recommended. Additionally, 
Ferrero et al described a prompt regression of hepatotoxicity 
after the addition of steroids that allowed imatinib continu-
ation and achievement of a complete cytogenetic response 
in three chronic phase patients (Ferrero et al 2006). More-
over, after a few months steroids were discontinued without 
recurrence of hepatotoxicity in spite of increased imatinib 
dosage in two patients up to 600 mg and 800 mg per day, 
respectively. Therefore, corticosteroids now can be regarded 
as a promising approach in imatinib-induced hepatotoxicity 
to avoid the permanent discontinuation of a very effective 
anti-neoplastic drug (Ferrero et al 2006). Anyway, as with 
other severe side effects second generation tyrosine kinase 
inhibitors now provide an opportunity to switch such patients 
to an alternative treatment, they are more likely to tolerate.
Pulmonary toxicity
Cases of interstitial lung disease (ILD) attributed to imatinib 
have been published (Bergeron et al 2002; Ma et al 2003; 
Rosado et al 2003; Isshiki et al 2004) and reviewed (Atallah 
et al 2007a). A lager series reported 27 cases of ILD in 
patients treated with imatinib (Ohnishi et al 2006). Eleven 
of those patients had a pre-existing lung disease. In most of 
the patients ILD was treated with steroids, with a complete 
resolution in 7 patients and an improvement in 16 patients. 
Four of the 11 patients in whom imatinib was reintroduced 
after ILD improved experienced relapsing ILD. Although 
ILD associated with imatinib is probably rare, physicians 
should be alert to it. Management should include appropriate 
supportive measures, steroids and the discontinuation of 
imatinib. A decision about the eventual reintroduction 
should be based on the individual clinical characteristics 
and course, but in severe cases not promptly responding 
to steroids switching to an alternative treatment would be 
prudent.
Other side effects
Similar to conventional cytoreductive chemotherapy, ima-
tinib can cause a tumor lysis syndrome, requiring an appro-
priate management including prophylaxis for patients who 
are at risk (Ali et al 2007).
Novartis reported a statistically signiﬁ  cant increase of 
renal, bladder, and preputial/clitorial tumors in rats after 
2 years of imatinib administration (Drug label). Addition-
ally Roy et al (2005) suggested an increased incidence of 
urothelial carcinomas in their patient population. Despite 
these concerns there was no increase of urothelial tumors 
observed in 9500 patients enrolled on the various clinical 
trials (Pilot et al 2006).
Drug interactions
Interactions may occur between imatinib and inhibitors 
or inducers of CYP3A4 and CYP3A5 enzymes leading to 
changes in the plasma concentration of imatinib as well as 
that of co-administered drugs (Peng et al 2005). Agents 
that inhibit CYP3A4/5 might result in increased levels of 
imatinib. This substance class includes several clinically 
important drugs (eg, clarithromycine, cyclosporine A, ﬂ  uox-
etine, erythromycine, indinavir, itraconazole, nelﬁ  navir, rito-
navir, saquinavir, sertraline, verapamil, and voriconazole). Therapeutics and Clinical Risk Management 2008:4(1) 173
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Grapefruit juice is another inhibitor of CYP3A4 inhibitor, 
and patients should be cautioned against excessive intake 
(Deininger et al 2003). Allelic variants of the genes coding 
for the cytochrome P-450 have been shown to exert limited 
effects on imatinib pharmacokinetics (Gardner et al 2006). 
Although imatinib possesses a wide therapeutic window, 
caution still needs to be exercised, particularly in patients 
on higher imatinib doses or patients already experiencing 
dose related toxicities.
Plasma levels of some drugs, which are themselves 
metabolized by CYP3A4/5 also can be increased by imatinib 
(eg, cyclosporine A, simvastatin), which is particularly 
important in substances with a narrow therapeutic 
window. Conversely, drugs known to induce CYP3A4/5 
may decrease the levels of imatinib. Major inductors 
of CYP3A4/5 include carbamazepine, dexamethasone, 
phenytoin, phenobarbital, rifampicin, St. John´s wort, and 
others.
In general, any co-medication with CYP3A4/5-inducing 
agents such as anticonvulsants and steroids should be used 
with caution and appropriate alternatives should be substi-
tuted if possible (Deininger et al 2003).
Imatinib is a weak inhibitor of CYP2D6 and CYP2C9. 
Therefore, drugs metabolized by these enzymes (eg, warfarin) 
should also be used with caution (Deininger et al 2003). 
Imatinib also has been shown to inhibit the O-glucuronidation
in vitro, possibly increasing the effect of Acetaminophen.
Resistance to imatinib
Types of resistance
In principle, there are two types of imatinib resistance: (1) 
Primary resistance deﬁ  ned as a lack of response to initial 
imatinib-treatment. (2) Acquired or secondary resistance: that 
is loss of beneﬁ  t of imatinib after initial response. In clinical 
studies imatinib failure was further subdivided into hematologic 
(lack of normalization of spleen size, peripheral blood counts, 
etc.), cytogenetic (lack of remission of Ph-positive cells), or 
molecular resistance (lack of a more than 3log reduction of 
Bcr-Abl transcript compared to a standardized baseline or a 
Bcr-Abl/Abl ratio of  0.1%).
Molecular mechanisms
The mechanisms of resistance to imatinib in CML have been 
investigated extensively both in preclinical imatinib resistant 
cell line models (Issaad et al 2000; le Coutre et al 2000; 
Mahon et al 2000; Weisberg and Grifﬁ  n 2001; Keeshan et al 
2001; Barnes et al 2005) as well as in primary patient samples 
(Barthe et al 2001; Gorre et al 2001; Hochhaus et al 2002; 
Shah et al 2002; Roche-Lestienne et al 2002; von Bubnoff 
et al 2002; Branford et al 2004). In principle, failure to con-
trol CML by treatment with imatinib can be caused by three 
entirely different biological mechanisms (van der Kuip et al 
2005). (1) imatinib fails to inhibit the kinase activity of Bcr-
Abl effectively (target-dependent resistance). (2) Growth and 
survival of the malignant clone is independent of the Bcr-Abl 
kinase activity (target independent resistance). (3) The avail-
ability of the drug within the cell is not sufﬁ  cient to inhibit 
the Bcr-Abl kinase activity (drug dependent resistance).
Target dependent resistance
Despite continued treatment with imatinib, the kinase 
activity and the activation of Bcr-Abl downstream targets 
remain high. This can be caused by different mechanisms. 
First, ampliﬁ  cation of the bcr-abl gene and consequently the 
production of a higher amount of Bcr-Abl protein has been 
observed in cell line models selected for imatinib resistance 
(le Coutre et al 2000; Mahon et al 2000; Weisberg and Grifﬁ  n 
2001). Multiple copies of the bcr-abl gene have also been 
detected in interphase nuclei from imatinib resistant CML 
patients by the use of a ﬂ  uorescence in situ hybridization 
assay (Gorre et al 2001; Hochhaus et al 2002).
A much more frequent cause of target dependent 
resistance are single amino acid (AA) changes within the 
Abl kinase domain of Bcr-Abl that lead to an active Bcr-
Abl kinase, but that reduce the binding afﬁ  nity of imatinib 
to the protein (Gorre et al 2001; von Bubnoff et al 2002; 
Hochhaus et al 2002; Cowan-Jacob et al 2004). This reduced 
binding capacity can be caused by either direct or indirect 
mechanisms, allowing a classiﬁ  cation of Bcr-Abl mutations 
into two groups (Table 2). (1) Mutations that directly impede 
the contact between Bcr-Abl protein and imatinib (Azam 
et al 2003): approximately 20 AA are involved in imatinib 
binding. Substitution of one of these can result in reduced 
afﬁ  nity of imatinib to Bcr-Abl or in steric inhibition of the 
binding. Examples of mutations that inhibit imatinib binding 
are those that affect Thr315 and Phe317. The clinically 
important Thr315Ile mutation is viewed to be homolog to 
the Thr670Ile mutation in c-Kit, Thr674Ile in PDGFR-α, and 
the Thr790Met mutation in EGFR in the sense of affecting the 
so-called gatekeeper threonine residue which is an important 
determinant of inhibitor binding to the kinase domains (Carter 
et al 2005). (2) Mutations that alter the spatial conformation 
of the protein leading to an indirect loss of imatinib binding 
afﬁ  nity (Azam et al 2003): mutations in the nucleotide-
binding loop (P-loop) and in the activation loop (A-loop) 
destabilize their arrangement such that imatinib cannot bind Therapeutics and Clinical Risk Management 2008:4(1) 174
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to the inactive kinase domain of Bcr-Abl anymore. Examples 
of mutations that destabilize the inactive conformation are 
those that affect residues Glu255, Tyr253, and Gly250 within 
the P-loop of the kinase domain (Schindler et al 2000; Shah 
et al 2002; Corbin et al 2003). In patients and in in vitro 
screens a set of more than 50 different point mutations 
leading to a more or less pronounced resistance to imatinib 
have been described (von Bubnoff et al 2002; Shah et al 
2002; Hochhaus et al 2002; Azam et al 2003; von Bubnoff 
et al 2005). Most of these mutations are relatively rare, and 
the most common mutations (affecting Gly250, Tyr253, 
Glu255, Thr315, Met351, and Phe359) account for 60%–70% 
of all mutations. In patient samples and in in vitro generated 
mutants imatinib resistance was always associated with 
mutations within the kinase domain, including the activation
loop, P-loop, and the hinge region that links the C- and 
N-terminal lobes of the kinase domain to form the ATP binding
cleft. The localization of the most important mutations within 
the kinase domain is shown in Figure 2. In addition to these 
kinase domain mutations, both in laboratory-generated 
mutants and in patients, mutations were also identiﬁ  ed in 
other regions outside the kinase domain. These regions, 
like SH3, SH2, and the linker between SH2 and the kinase 
domain are required to maintain the inactive conformation 
of the kinase (Hochhaus et al 2002; Azam et al 2003).
In vitro studies demonstrated that different imatinib resis-
tant mutants can have different oncogenic potential, with a 
ranking list of the transforming capacity being Tyr253Phe, 
Glu255Lys wtBcr-Abl Thr315Ile His396Pro Met351Thr 
(Griswold et al 2006; Skaggs et al 2006). The two mutations 
with the greatest transforming ability (Tyr253Phe and 
Glu255Lys, both in the P-loop of the kinase domain) are also 
two of the most frequently detected mutations in patients. 
Importantly, P-loop mutations together with the Thr315Ile 
mutation are more frequently found in patients with advanced 
disease and seem to be closely associated with progression 
of patients from chronic phase to accelerated phase or blast 
crisis (Soverini et al 2006).
Table 2 Mechanisms, frequencies, and functional consequences on proliferation of relevant bcr-abl mutations
Mutation  Mechanism of resistance  Frequency in patients  in vitro proliferation IC50 [nM]
  direct  indirect  high  low or   Imatinib  Nilotinib  Dasatinib
       medium    
wt         260  13  0.8
Met244Val   +   + 2000  38  1.3
Leu248Val  +   +     675 
Gly250Ala     +   1350 48  1.8
Gly250Glu (P-loop)    +   +    
Gln252His (P-loop)    +   + 1325  70  3.4
Gln252Arg (P-loop)    +   +    
Tyr253His (P-loop)  +  +  +    6400 450  1.3
Tyr253Phe (P-loop)    +  +   3475 125  1.4
Glu255Lys (P-loop)    +   + 5200  200  5.6
Glu255Val (P-loop)    +   +   6400 430  11
Glu292Lys       +    
Phe311Ile   +   +    
Phe311Leu   +   + 480  23  1.3
Thr315Ile  +   +    6400   2000   200
Phe317Leu  +   +   1050 50  7.4
Phe317Val  +    + 350    53
Met343Thr   +   +    
Met351Thr   +  +   880  15  1.1
Glu355Gly    +   2300   1.8
Phe359Ala  +    +    
Phe359Val  +   +   1825 175  2.2
Val379Ile   +   + 1630  51  0.8
Met388Leu (A-loop)    +   +    
His396Arg (A-loop)    +  +      
His396Pro (A-loop)    +   + 850  41  0.6
Phe486Ser   +   +    
Adapted from Ray et al (2007), Weisberg et al (2007), O´Hare et al (2005), and O´Hare et al (2007). 
The IC50 value is the concentration of inhibitor resulting in a 50% reduction of BaF3 cellular proliferation. Therapeutics and Clinical Risk Management 2008:4(1) 175
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Several studies suggest that imatinib resistant mutations 
can arise during imatinib treatment (Branford et al 2002; 
Muller et al 2002). However, highly sensitive screening 
assays (such as allele-speciﬁ  c oligonucleotide (ASO) PCR 
and the denaturing high – performance liquid chromatography 
(D-HPLC)) allowed the detection of low-level mutations 
in newly diagnosed and in pretreated, but imatinib-naive 
CML and ALL patients before imatinib treatment (Hofmann 
et al 2003; Willis et al 2005; Pfeifer et al 2007). Therefore, 
imatinib resistant mutations might also exist before imatinib 
treatment in a small sub-clone ( 1%) of tumor cells.
Target independent resistance
Bcr-Abl independence appears to be a rare phenomenon in 
patients with newly diagnosed chronic myelogenous leuke-
mia (CML). Less than 5% of the patients do not respond to 
treatment with the standard dose of 400 mg per day imatinib 
(Kantarjian et al 2002a; O´Brien et al 2003). In contrast, 
patients with late stage CML more frequently exhibit pri-
mary resistance to Bcr-Abl inhibition. Only roughly 30% 
of patients with accelerated phase or blastic phase of CML 
respond to this treatment (Sawyers et al 2002; Talpaz et al 
2002; Kantarjian et al 2004a; Silver et al 2004). Recent 
research has focused on the involvement of Bcr-Abl inde-
pendent pathways that trigger the progression of the disease, 
in particular, the PI3K-mTOR pathway and the Src family 
kinases. Lyn and Src support cell survival and are also criti-
cal in development of some Bcr-Abl dependent leukemias 
(Lionberger et al 2000; Donato et al 2003; Dai et al 2004; Hu 
et al 2004). Bcr-Abl positive cells cultured in the continuous 
presence of imatinib show a reduced Bcr-Abl protein level 
and an increase of expression of Src kinases (Donato et al 
2003). The role of Src kinases for imatinib resistance has been 
further supported by the ﬁ  nding that siRNA-mediated inhibi-
tion of Lyn expression signiﬁ  cantly reduced proliferation and 
survival of imatinib resistant Bcr-Abl positive cells (Ptasznik 
et al 2004). The PI3K-mTOR pathway can be activated by 
imatinib treatment both in vitro and in vivo. PI3K activation 
was found to be a critical mediator of cell survival during 
the early onset of imatinib treatment before manifestation 
of mutations within the kinase domain leading to a robust 
resistance. This effect can be effectively antagonized by 
pharmacological inhibition of mTOR or AKT-speciﬁ  c siRNA 
treatment in vitro (Burchert et al 2005).
Recently, a potential role for autocrine GM-CSF secre-
tion as a counterregulatory mechanism of Bcr-Abl positive 
cells to resist imatinib and nilotinib has been reported (Wang 
et al 2007).
Drug dependent resistance
Cellular drug efﬂ  ux pumps or trapping of the drug by binding 
proteins have been proposed to cause decreased intracellular 
levels of imatinib. An increase in the serum level of the 
A1AGP causing a decreased bioavailability of imatinib 
has been proposed as a mechanism favoring resistance 
(Gambacorti-Passerini et al 2000). The role of the A1AGP-
imatinib binding and the thereby reduced distribution of 
imatinib from the blood for resistance is controversial. In 
vitro experiments using blasts from patients showed that 
A1AGP, at concentrations observed in patients, can reduce 
the concentration of imatinib roughly 10-fold (Gambacorti-
Passerini et al 2003). However, there is no correlation 
between elevated A1AGP levels with imatinib resistance, 
despite the fact that about 50% of CML patients have higher 
A1AGP level (le Coutre et al 2002).
Drug transporters play a major role in the regulated 
transport of drugs across the cellular membrane and therefore 
in determining drug bioavailability and intracellular drug 
concentrations. It has become evident that transporter 
Figure 2 Position of relevant AA substitutions within the Abl kinase causing resist-
ance to imatinib.   The structure of Abl is shown in its inactive status bound to imatinib. 
Relevant AA are highlighted in yellow. Derived from Nagar et al (2002).Therapeutics and Clinical Risk Management 2008:4(1) 176
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proteins contribute substantially to the cellular uptake and 
efﬂ  ux of imatinib: in vitro experiments have demonstrated 
that in leukemic cells the uptake of imatinib is strongly 
temperature-dependent corroborating an active transport 
process (Thomas et al 2004). Imatinib is a substrate of the 
human organic cation transporter 1 (hOCT1), but not for 
hOCT2 or hOCT3 (Thomas et al 2004). Imatinib clearance 
is most strongly associated with the multi drug resistance 
transporter P-glycoprotein the gene product of the multi drug 
resistance gene 1 (MDR1), also termed as ABCB1 (Illmer 
et al 2004) and by the breast cancer resistance protein BCRP 
(ABCG2; Ozvegy-Laczka et al 2004; Burger et al 2004). 
Interestingly, imatinib is both a substrate and an inhibitor 
of BCRP (Burger et al 2004; Houghton et al 2004). This 
is the reason why BCRP mediated resistance to imatinib is 
attenuated by imatinib induced reduction of BCRP expression 
(Nakanishi et al 2006).
Strategies to overcome resistance
Further understanding of the reasons of transient responses 
and complete resistance to imatinib has provided the opportu-
nity to develop strategies that are able to overcome resistance. 
These include imatinib dose escalation, combining imatinib 
with other agents, and novel Bcr-Abl inhibitors.
Novel Bcr-Abl inhibitors
Expanded knowledge on the different mechanisms of imatinib 
resistance clearly aids in the development of novel tyrosine 
kinase inhibitors. One goal was to identify compounds that 
bind to and inhibit Abl kinase but are less affected by bcr-
abl point mutations. In particular, crystal structure analysis 
of the Abl-imatinib complex (Figure 2) has been helpful in 
the identiﬁ  cation of potential critical residues that hinder 
the interaction of imatinib with mutated Bcr-Abl (Schindler 
et al 2000).
Nilotinib (TasignaTM)
Nilotinib (TasignaTM, AMN107) is an anilinopyrimidine 
derivative structurally related to imatinib (Figure 1). Similar 
to imatinib, nilotinib binds to Abl in its inactive conforma-
tion. Nilotinib exerts a signiﬁ  cantly higher potency on wild 
type Bcr-Abl (Weisberg et al 2005 and 2006) and most 
imatinib-resistant Bcr-Abl mutants are effectively targeted by 
nilotinib (Table 2). However, clones carrying the Leu248Val, 
Tyr253Cys, Tyr253His, Glu255Lys, Lys285Asn, and 
Thr315Ile mutations are markedly resistant, even at high 
doses in vitro (Weisberg et al 2007; Inokuchi 2006; Ray 
et al 2007).
For nilotinib, antileukemic activity and a relatively 
favorable safety proﬁ  le have been demonstrated in patients 
with imatinib-resistant CML in an international phase I trial 
(Kantarjian et al 2006a). In addition, promising phase II 
results have been reported (Kantarjian et al 2006b; Giles et al 
2006a; Ottmann et al 2006; Giles et al 2007a; le Coutre et al 
2007). After its approval in Switzerland the manufacturer 
now is hoping to launch its second-generation Bcr-Abl 
inhibitor, nilotinib, in the very near future in other countries. 
Recently nilotinib was reported to possess a very low rate 
of cross-intolerance in imatinib-intolerant patients (Jabbour 
et al 2007). Thus approval of nilotinib clearly will expand 
therapeutic options for imatinib-intolerant or imatinib-
resistant patients.
Dasatinib (SprycelTM)
The pyridol [2,3-d] pyrimidine dasatinib (SprycelTM, BMS-
354825, Figure 1) is another novel Abl-targeted kinase 
inhibitor, which additionally displays an inhibitory activity 
against Src kinases.
Compared with imatinib, dasatinib is more potent and 
binds to the active conformation of the Abl kinase domain 
(Figure 3, middle panel). In addition, dasatinib showed in 
vitro activity against 14 of 15 imatinib-resistant bcr-abl 
mutations. The gatekeeper mutation Thr315Ile mutation was 
the only resistant variant of Abl (Table 2) (Shah et al 2004). 
Meanwhile, other bcr-abl mutations have been reported to 
confer resistance towards dasatinib in vitro (eg, Val299Leu, 
Thr315Ala, and Phe317Val) (Burgess et al 2005; Shah et al 
2006a).
Acquired resistance in patients treated with dasatinib 
seems almost invariably associated with a small set of tyrosine 
kinase domain mutations. Thus, once the malignant clone is 
fully committed to Bcr-Abl, activating a Bcr-Abl independent 
transformation program appears to be difﬁ  cult, leaving tyrosine 
kinase mutations as the most important escape mechanism for 
the neoplasia. This experience is strikingly different from that 
in patients with acute myeloid leukemia (AML) developing 
acquired resistance to FLT-3 inhibitors (O´Hare et al 2007).
Dasatinib-induced hematologic and cytogenetic responses 
in patients with CML or Ph-positive ALL intolerant or resistant 
to imatinib (Talpaz et al 2006). Clinical efﬁ  cacy was further 
established in 4 single-arm studies, including a total of 445 
extensively pretreated patients with CML in different phases 
or Ph-positive ALL. Initial dose of dasatinib was 70 mg twice 
daily. The substance was generally well tolerated; however, 
dose interruptions due to cytopenias or nonhematologic 
toxicities were not uncommon. Of note, pleural effusions Therapeutics and Clinical Risk Management 2008:4(1) 177
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occurred more often as expected from the prior experience 
with imatinib. Clearly, the observed adverse events have to 
be noticed but might be considered partially acceptable in 
light of the available alternative therapeutic options in these 
patients. The observed pleural effusions were reversible 
with dose interruption and diuretic or steroid administration. 
In chronic phase CML patients´ treatment resulted in 90% 
complete hematologic responses and 52% major cytogenetic 
responses after 8 month of follow-up and only 2% of the 
patients achieving major cytogenetic responses progressed or 
died (Hochhaus et al 2007). In accelerated phase, 81%, 64%, 
and 39% of patients achieved overall, major and complete 
hematologic responses, respectively, while 33% and 24% 
attained major and complete cytogenetic remissions at 8 
months minimum follow-up. Of 69 patients who achieved 
a major hematologic remission only 7 progressed and 66% 
of patients are estimated to be alive and progression-free 
after 10 months (Guilhot et al 2007). In patients with blast 
crisis, dasatinib induced major hematologic responses in 34% 
and 31% of myeloid blast crisis and lymphoid blast crisis, 
respectively. Of note, 31% and 50% of these patients achieved 
a major cytogenetic response. Responses were rapid and 
durable and 86% of patients with a major cytogenetic response 
were complete cytogenetic responders (Cortes et al 2007). 
Importantly, comparable response rates were achieved by 
patients with or without bcr-abl mutations conferring imatinib 
resistance in these trials. So far available evidence clearly 
indicates that dasatinib is effective in overcoming resistance 
and intolerance to imatinib and in June 2006 the FDA granted 
accelerated approval to dasatinib for use in the treatment of 
adults with chronic phase, accelerated phase, and myeloid 
or lymphoid blast phase CML with resistance or intolerance 
to prior therapy, including imatinib. Towards the recent 
publication of a randomized comparison of high-dose imatinib 
(800 mg per day) versus standard dose dasatinib (140 mg per 
day) after failure of ﬁ  rst-line imatinib in an international phase 
II trial the latter treatment option clearly appears favorable. 
With a median follow-up of 15 months, complete hematologic 
responses were observed in 93% and 82% of patients receiving 
dasatinib and high-dose imatinib (p = 0.034), respectively. 
Dasatinib resulted in signiﬁ  cantly higher major (52% versus 
33%) and complete (40% versus 16%) cytogenetic response 
rates. Major molecular responses (16% versus 4%) were also 
more frequent with dasatinib. Additionally, treatment failure 
and progression-free survival favored dasatinib (Kantarjian 
et al 2007a). However, the majority of these patients have 
failed to treatment with 600 mg imatinib before entering the 
trial. Therefore, the question whether dasatinib is superior to 
dose escalation of imatinib is not deﬁ  nitely settled.
Data from a trial of 4 different dose schedules, including 
the standard dose of  2 × 70 mg per day, scrutinized the optimal 
dosage of dasatinib. All dosing levels had similar efﬁ  cacy as 
Figure 3 Structure of the Abl kinase in complex with imatinib (red, left panel), dasatinib (red, middle panel), and MK-0457 (red, right panel).   The positions of the P-loop and 
the activation loop are indicated in yellow. Imatinib binds and stabilizes the inactive conformation of Abl (left panel) whereas dasatinib binds to the active conformation of the 
Abl kinase which is similar for Src and Abl (middle panel). MK-0457 (left panel) is not fully buried in the kinase domain and is anchored to this domain by 4 hydrogen bonds 
to sequence-invariant elements within the active form of Abl. Derived from Nagar et al (2002), Tokarski et al (2006), and Young et al (2006).Therapeutics and Clinical Risk Management 2008:4(1) 178
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reﬂ  ected by hematologic and cytogenetic responses, but the 
100 mg once a day schedule had a favorable adverse event 
proﬁ  le with a reduced incidence of cytopenias (Hochhaus et al 
2006). Rapid, complete cytogenetic responses to dasatinib 
100 mg per day have been observed in a high percentage 
of patients in an ongoing trial with dasatinib as ﬁ  rst-line 
treatment for chronic phase CML (Atallah et al 2007b).
Bosutinib (SKI-606)
Bosutinib (SKI-606) is a 4-anilino-3-quinolinecarbonitrile 
Src/Abl kinase inhibitor. Bosutinib can bind to and inhibit 
several imatinib-resistant Abl mutants, but not Thr315Ile 
(Soverini et al 2007; Weisberg et al 2007). Initial clinical trials 
are underway on both sides of the Atlantic and the substance 
already showed evidence of efﬁ  cacy in imatinib resistant or 
intolerant patients with cytogenetic responses and complete 
hematologic responses across a range of BCR-ABL mutations 
(Cortes et al 2006; Gambacorti-Passerini et al 2007).
INNO-406
INNO-406 (NS-187) is an orally available, dual Abl/Lyn 
kinase inhibitor which is structurally related to imatinib 
and nilotinib but much more potent than imatinib in vitro. 
Numerous Bcr-Abl mutants, but not Thr315Ile, are sensitive 
to the substance (Weisberg et al 2007). INNO-406 showed 
encouraging evidence of clinical activity in imatinib-resistant 
patients in a phase I trial (Craig et al 2007) and is currently 
evaluated in ongoing trials. Unlike imatinib this new Abl 
inhibitor appears to cross the blood–brain barrier in a murine 
model system (Yokota et al 2007).
ON012380
Unlike imatinib, the Abl inhibitor ON012380 (Figure 1) 
was speciﬁ  cally designed to block the substrate binding site 
rather than the ATP binding site. A feature that gives the 
advantage that the previously described imatinib-resistant 
mutants are unlikely to be resistant to this novel inhibitor, due 
to their different binding sites. As expected, in vitro studies 
conﬁ  rmed this assumption and ON012380 has been shown 
to inhibit wild-type and all tested imatinib-resistant kinase 
domain mutations, including the Thr315Ile mutation, with 
an IC50 of less than 10nM (Gumireddy et al 2005). Besides 
Abl, ON012380 showed inhibitory activity against PDGFR 
kinases and the Src family member Lyn.
Aurora kinase inhibitors
Aurora kinases (AK) are essential for the regulation of mitotic 
chromosome segregation and cytokinesis. Aberrant AK 
activity has been described in many human tumors (Matthews 
et al 2006). Bcr-Abl stimulates several signal transduction 
pathways, including the Janus kinase 2 (JAK2) pathway. 
The activation step of JAK2 involves phosphorylation of 
the critical Tyr1007 residue (Xie et al 2001). One major 
effect of the JAK2 activation by Bcr-Abl is the increase 
in c-Myc expression (Xie et al 2002) which is important 
for leukemia induction (Sawyers et al 1992). Samanta et al 
(2006) identiﬁ  ed JAK2 as a potentially important therapeu-
tic target for CML. MK-0457 (VX-680), a small molecule 
inhibitor targeting AK, FLT-3 and JAK2 and with the abil-
ity to block cell cycle progression and induce apoptosis in 
diverse human tumor types (Harrington et al 2004) has been 
shown to possess preclinical and clinical activity in CML 
harboring Thr315Ile mutated Bcr-Abl without signiﬁ  cant 
extramedullary toxicity in preliminary trials (Bergstrom et al 
2006; Giles et al 2006b; Shah et al 2006b; Giles et al 2007b). 
These fascinating results may indicate the possibility to 
develop targeted treatment approaches interacting with Bcr-
Abl-induced pathways rather than Bcr-Abl itself. However, 
MK-0457 has also been shown to bind to and inhibit the Abl 
kinase (Young et al 2006; Buser et al 2007; Cheetham et al 
2007) in a mode that accommodates the substitution of the 
bulkier isoleucine for threonine at residue 315 (Figure 3, 
left panel), but the relative contributions of AK, JAK-2, and 
Bcr-Abl inhibition in the activity of MK-0457 have not been 
elucidated (Giles et al 2007b).
Whatever the key mechanism of MK-0457 action in 
Thr315Ile Bcr-Abl positive CML is, the observations of Giles 
et al and others may set the starting point for a breakthrough 
in the management of patients with the Thr315Ile mutation, 
for whom presently no other effective targeted therapy exists 
(Martinelli et al 2007).
Combination of imatinib with other substances
Interferon-α
Interferon-α is clinically effective in the treatment of CML 
with a different mechanism of action than imatinib and 
its combination with imatinib might facilitate eradication 
of leukemic cells. Interestingly, the addition of pegylated 
interferon-α in CML patients with a durable imatinib-induced 
complete cytogenetic remission was shown to improve 
molecular response (Hardan et al 2006). This observation 
is encouraging in the attempt of using combined modality 
approaches in the treatment of CML patients. The interest in 
combination therapies using these agents has resulted in the 
design of clinical trials referring to this (eg, the German CML 
IV trial) (Hehlmann et al 2005) with early results already 
reported (Gardembas et al 2003; Baccarani et al 2004). Therapeutics and Clinical Risk Management 2008:4(1) 179
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Despite promising efﬁ  cacy enhanced toxicity due to such 
combinations clearly remains an issue of concern.
Farnesyltransferase inhibitors
Preclinical studies have demonstrated the activity of farnesyl-
transferase inhibitors (FTI) such as lonafarnib as single agents 
against Bcr-Abl positive cells from CML patients and Bcr-
Abl-induced leukemia in a mouse model (Peters et al 2001). 
Lonafarnib also inhibits proliferation of imatinib-resistant 
CML cell lines and primary cells from imatinib-resistant 
patients (Hoover et al 2002). In addition, some in vitro studies 
suggest that lonafarnib may reduce the number of dormant, 
possibly imatinib-insensitive CML stem cells when combined 
with imatinib (Jorgensen et al 2005). In a recently published 
pilot study, the efﬁ  cacy of this FTI was investigated in a cohort 
of 13 CML patients in chronic and accelerated phase who had 
failed prior imatinib and interferon-α therapy (Borthakur et al 
2006). Two patients had a transient hematological response 
(Borthakur et al 2006). Lonafarnib has also been combined 
with imatinib in a phase I study with 22 patients who had 
failed imatinib therapy. Roughly 30% of patients achieved 
hematological remission (Cortes et al 2004).
Hypomethylating agents
Promotor hypermethylation may also play a role in progression 
of CML (Zion et al 1994; Nguyen et al 2000). 5-aza-
2´-deoxycytidine (decitabine, DAC), a hypomethylating 
agent, has been investigated in CML. In early clinical trials, 
this compound was used as single agent at doses of 50–100 
mg/m2 over 6 hours every 12 hours for 5 days every 4–8 weeks 
(Kantarjian et al 2003b). 55% (28 of 55) patients in accelerated 
phase and 28% (18 of 64) patients in blast crisis achieved a 
hematological response. Because of its myelosuppressive 
effect, with infections occurring in 34% of patients, lower 
dosages of decitabine are now favored. A dose of 15 mg/m2 
daily for 10 days was given to 35 patients with imatinib failure; 
12 in chronic phase and 17 in accelerated phase. Complete 
hematological response was reported in 12 patients, 7 patients 
had a partial hematological response (Issa et al 2005). In 
a phase II study with the same schedule, 28 patients were 
enrolled, 25 with imatinib resistance. Complete hematological 
response was observed in 32% (Oki et al 2007). Interestingly, 
the response rate was higher in patients without Bcr-Abl kinase 
domain mutations (53% versus 14%).
Other agents
Combination strategies involving imatinib and other agents 
are currently under investigation. These include PI3K/mTOR 
inhibitors, bcr-abl RNA interference, histone deacetylase 
inhibitors, and others. Phosphatidylinositol 3-kinase (PI3K) 
and its downstream substrate mTOR are critical for survival 
and proliferation of Bcr-Abl transformed cells. The mTOR 
inhibitors rapamycin (Sirolimus) and RAD001 (Everolimus) 
have been shown to inhibit proliferation in CML cell lines, 
and it has been demonstrated that rapamycin and imatinib 
act synergistically in Bcr-Abl transformed cell lines (Ly 
et al 2003; Mohi et al 2004). Concerning the Thr315Ile 
mutation, conﬂ  icting data have been reported on the effects 
of imatinib and rapamycin. Mohi et al (2004) found these 
compounds to act synergistically on that imatinib resistant 
phenotype, whereas Ly et al (2003) and Dengler et al (2005) 
found no effect of imatinib or rapamycin in Thr315Ile Bcr-
Abl positive cells. Combination treatment of imatinib with 
mTOR inhibitors could be effective in cases where Bcr-
Abl mutants do not cause complete resistance to imatinib 
(Dengler et al 2005).
Decreasing the protein expression of a target kinase is 
also capable of restoring sensitivity to imatinib in cells over-
expressing bcr-abl as well as in cells expressing a mutant 
bcr-abl variant conferring partially resistance to imatinib. 
In vitro experiments demonstrated that cells expressing the 
His396Pro variant of Bcr-Abl reverted to an imatinib sensi-
tive state upon reduction of the Bcr-abl protein content with 
breakpoint speciﬁ  c siRNAs (Wohlbold et al 2003).
Treatment strategies 2007
The treatment options presently available for chronic phase 
CML include hydroxyurea, interferon-α, interferon-α plus 
cytarabine, imatinib, dasatinib, and allogeneic SCT (SCT). 
Nilotinib is currently approved in Switzerland but expected 
to be available in other countries in the very near future. Up 
to now allogeneic SCT is the only treatment option provid-
ing deﬁ  nitive cure in about 50% of the patients eligible for 
the procedure. However, the treatment related risks clearly 
exceed the risk of disease progression upon treatment with 
imatinib. Imatinib 400 mg per day is well tolerated and 
clearly superior to any other treatment up to 6 years of obser-
vation. This hopefully will end up in an excellent long-term 
outcome but to date follow-up with imatinib is not sufﬁ  cient 
to draw ﬁ  rm conclusions on the 10-year or 20-year results. 
Prospective studies comparing 400 mg daily with a higher 
dosage of imatinib have been initiated to optimize treatment 
in chronic phase CML but 400 mg per day remains today’s 
standard of care. First line allogeneic SCT may still be an 
option exclusively for very young patients with unfavorable 
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Clearly, response to imatinib treatment and tolerability has 
to be monitored appropriately. The deﬁ  nition of an appropriate 
response is dependent on the extent of remission at certain time 
points after initiation of treatment. For this, speciﬁ  c recommen-
dations have been issued (Deininger et al 2003; Baccarani et al 
2006; Branford et al 2006; Hughes et al 2006). However, even 
close monitoring will not always detect relapse early, as some 
patients have progressed directly to accelerated phase or blast 
crisis, even from complete cytogenetic remission (Deininger 
2005). Deﬁ  nition of response, treatment failure, suboptimal 
response, and recommendation for appropriate action for 
patients with early chronic phase CML treated with 400 mg 
imatinib per day have been presented by Baccarani et al in 2006 
(Table 3). A complete hematologic response (CHR) is deﬁ  ned 
as follows: Platelet count  450 × 109/L, WBC count  10 × 
109/L, differential without immature granulocytes and with less 
than 5% basophils, nonpalpable spleen. The level of cytogenetic 
response (CgR) is classiﬁ  ed as follows, according to the mor-
phologic cytogenetic evaluation of at least 20 marrow meta-
phases: Complete CgR 0% Ph+, partial or major CgR 1%–35% 
Ph+, minor CgR 36%–65% Ph+, minimal CgR 66%–95% Ph+, 
no CgR   95% Ph+. Molecular response (MolR) is assessed in 
the peripheral blood and a complete MolR indicates Bcr-Abl 
transcript nonquantiﬁ  able and nondetectable. A major MolR 
is deﬁ  ned as more than 3log reduction of Bcr-Abl transcript 
compared to a standardized baseline or a Bcr-Abl/Abl ratio of 
 0.1%). Complete CgR and major MolR should be conﬁ  rmed 
on two subsequent occasions.
In cases of failure or suboptimal response, the options 
available are either dose escalation of imatinib, dasatinib, 
investigational TK-inhibitors (eg, nilotinib), allogeneic SCT, 
or interferon-α. If possible allogeneic SCT should be offered 
to patients before the disease progresses to an accelerated or 
blastic phase. However, the 2-year survival rates for second-
line treatment with nilotinib or dasatinib are superior compared 
to allogeneic SCT in chronic phase, but not in accelerated 
phase or blast crisis CML post-imatinib failure (Kantarjian et al 
2007b). Nevertheless, valid long-term survival comparisons 
between allogeneic SCT and non-transplant second line treat-
ment approaches post-imatinib failure are not available at the 
moment. Individual treatment decisions in patients failing or 
suboptimally responding on imatinib should appropriately take 
the patient’s individual situation and risk factors into account. 
Therefore, Kantarjian et al (2007b) developed a novel risk 
score in this group of patients, comprising splenomegaly and 
hematologic failure as independent poor prognostic factors. Of 
note, patients with target-independent mechanisms of imatinib 
resistance will most likely not obtain a sustained beneﬁ  t from 
speciﬁ  c Abl kinase inhibitors, and today these patients should 
proceed to allogeneic SCT if possible.
In a patient appearing with “warning signs”, standard 
treatment is still 400 mg imatinib, but physicians should be 
alert that the patient might become eligible for alternative 
treatment approaches as lined out above.
Monitoring of imatinib blood concentrations are not rec-
ommended routinely, but they could be desirable in cases of 
Table 3 Deﬁ  nition of failure and suboptimal response in ﬁ  rst-line imatinib treatment (400 mg)
  Failure  Suboptimal response  Warning signs
at diagnoses  NA  NA  High risk, del9q
      ACAs in Ph+ cells
3 months  No HR  Less than complete HR 
after diagnosis     
6 months  Less than complete HR   Less than partial CgR  
after diagnosis  No CgR (Ph+  95%) (Ph+  35%) 
12 months  Less than partial CgR  Less than complete CgR  Less than major MolR
after diagnosis  (Ph+  35%)  
18 months  Less than complete CgR  Less than major MolR
after diagnosis   
Anytime  Loss of complete HR1   ACA in Ph+ cells4  Any rise in transcript level
  Loss of complete CgR2  Loss of major MolR4  OCA in Ph− cells
 Mutation3 Mutation5 
Adapted with permission from Baccarani M, Saglio G, Goldman J, et al. 2006. Evolving concepts in the management of chronic myeloid leukemia:recommendations from an 
expert panel on behalf of the European LeukemiaNet. Blood, 108:1809–20. Copyright © 2006 American Society of Hematology.
1to be conﬁ  rmed on 2 occasions unless associated with progression to AP/BC.
2to be conﬁ  rmed on 2 occasions unless associated with loss of complete hematologic remission or progression to AP/BC.
3high level of insensitivity to imatinib (eg, Thr315Ile).
4to be conﬁ  rmed on 2 occasions unless associated with loss of complete hematologic remission or complete cytogenetic remission.
5low level of insensitivity to imatinib.
Abbreviations: NA, not applicable;   ACA, additional cytogenetic aberrations in Ph+ cells; OCA, other chromosomal abnormalities in Ph− cells; HR, hematologic remission; 
CgR, cytogenetic remission; MolR, molecular remission.Therapeutics and Clinical Risk Management 2008:4(1) 181
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failure and in patients who must take drugs interfering with the 
imatinib metabolism via cytochrome P-450 or have experienced 
severe drug-related adverse effect (Baccarani et al 2006).
In patients presenting with early blast crisis at the time 
of diagnosis initial treatment with imatinib (600 mg per day) 
or another tyrosine kinase inhibitor (based on mutational 
analysis) has been proposed (Baccarani et al 2006) followed 
by allogeneic SCT. In patients failing to respond to imatinib an 
alternative targeted approach or appropriate induction chemo-
therapy might be used to induce remission before transplant. 
Since remissions achieved with imatinib (600  mg per day) in 
accelerated phase CML clearly tend to be longer than in blastic 
crisis, a more prolonged trial with imatinib might be possible 
in these patients. However, whenever possible, allogeneic 
SCT should be discussed and planned in such cases.
Conclusions
Research has led to the understanding of the molecular 
mechanisms underlying CML and allowed the development 
of effective targeted therapies. Imatinib is a breakthrough 
not only for treatment of CML patients but also for the 
understanding how to advance targeted therapies for treat-
ment of other malignant diseases. In addition, unraveling 
the molecular mechanisms of imatinib resistance allowed 
the rapid development of second line drugs effective for the 
treatment of patients failing on imatinib therapy.
Cure of CML is not yet achieved by blocking the Bcr-Abl 
kinase. It remains the major challenge to completely eradicate 
the neoplastic cell clone in CML patients. However, the high 
number of potential drugs proven to inhibit or kill the Bcr-Abl 
positive cells allows the testing of innovative hypotheses in 
clinical studies to ﬁ  nally achieve this goal.
Acknowledgments
The authors are supported by the Robert Bosch Foundation. 
We are grateful to Dr Liza Bacchus and Ms Maike Sonnen-
berg for critical reading of the manuscript.
Disclosures
The authors have no conﬂ  icts of interest to disclose.
References
Al Sobhi E, Zahrani Z, Zevallos E, et al. 2007. Imatinib-induced immune 
hepatitis:case report and literature review. Hematology, 12:49–53.
Ali R, Ozkalemkas F, Ozkan A, et al. 2007. Tumour lysis syndrome with 
acute renal failure during imatinib therapy. Leuk Res, 31:573–4.
Ali R, Ozkalemkas F, Ozkocaman V, et al. 2004. Successful pregnancy and 
delivery in a patient with chronic myelogenous leukemia (CML), and 
management of CML with leukapheresis during pregnancy:a case report 
and review of the literature. Jpn J Clin Oncol, 34:215–7.
Aoki E, Kantarjian H, O’Brien SG, et al. 2006. High-dose imatinib provides 
better responses in patients with untreated early chronic phase CML 
[abstract]. Blood, 108:608a.
Atallah E, Kantarjian H, Cortes J. 2007a. Emerging safety issues with 
Imatinib and other Abl tyrosine kinase inhibitors. Clin Lymphoma and 
Myeloma, 3:105–12.
Atallah EL, Kantarjian H, O’Brien S, et al. 2007b. Use of dasatinib in patients 
(pts) with previously untreated chronic myelogenous leukemia (CML) 
in chronic phase (CP-CML) [abstract]. J Clin Oncol, 25:7006a.
Ault P, Kantarjian H, O’Brien S, et al. 2006. Pregnancy among patients 
with chronic myeloid leukemia treated with imatinib. J Clin Oncol, 
24:1204–8.
Azam M, Latek RR, Daley GQ. 2003. Mechanisms of autoinhibition and 
STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. 
Cell, 112:831–43.
Baccarani M, Martinelli G, Rosti G, et al. 2004. Imatinib and pegylated 
human recombinant interferon alpha2b in early chronic-phase chronic 
myeloid leukemia. Blood, 104:4245–51.
Baccarani M, Rosti G, de Vivo A, et al. 2002. A randomized study of 
interferon-alpha versus interferon-alpha and low-dose ara-binosyl 
cytosine in chronic myeloid leukemia. Blood, 99:1527–35.
Baccarani M, Russo D, Rosti G, et al. 2003. Interferon-alfa for chronic 
myeloid leukemia. Semin Hematol, 40:22–33.
Baccarani M, Saglio G, Goldman J, et al. 2006. Evolving concepts in the man-
agement of chronic myeloid leukemia:recommendations from an expert 
panel on behalf of the European LeukemiaNet. Blood, 108:1809–20.
Barnes DJ, Melo JV. 2002. Cytogenetic and molecular genetic aspects of 
chronic myeloid leukaemia. Acta Haematol, 108:180–202.
Barnes DJ, Palaiologou D, Panousopoulou E, et al. 2005. Bcr-Abl expres-
sion levels determine the rate of development of resistance to imatinib 
mesylate in chronic myeloid leukemia. Cancer Res, 65:8912–9.
Barthe C, Cony-Makhoul P, Melo JV, et al. 2001. Roots of clinical resist-
ance to STI-571 cancer therapy. Science, 293:2163.
Bergeron A, Bergot E, Vilela G et al. 2002. Hypersensitivity pneumonitis 
related to imatinib mesylate. J Clin Oncol, 20:4271–2.
Bergstrom DA, Clark JB, Xiao A, et al. 2006. MK-0457, a novel multikinase 
inhibitor, inhibits BCR-ABL activity in patients with Chronic Myeloid 
Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the 
T315I BCR-ABL Mutation [abstract]. Blood, 108:637a.
Berman E, Nicolaides M, Maki RG, et al. 2006. Altered bone and mineral 
metabolism in patients receiving imatinib mesylate. N Engl J Med, 
354:2006–13.
Beumer JH, Natale JJ, Lagattuta TF, et al. 2006. Disposition of imatinib 
and its metabolite CGP74588 in a patient with chronic myelogenous 
leukemia and short-bowel syndrome. Pharmacotherapy, 26:903–7.
Bonifazi F, de Vivo A, Rosti G, et al. 2001. Chronic myeloid leukemia and inter-
feron-α: a study of complete cytogenetic responders. Blood, 98:3074–81.
Bornhäuser M, Kröger N, Schwerdtfeger R, et al. 2006. Allogeneic haemat-
opoietic cell transplantation for chronic myelogenous leukaemia in the era 
of imatinib:a retrospective multicentre study. Eur J Haematol, 76:9–17.
Borthakur G, Kantarjian H, Daley G, et al. 2006. Pilot study of lonafarnib, 
a farnesyl transferase inhibitor, in patients with chronic myeloid leuke-
mia in the chronic or accelerated phase that is resistant or refractory to 
imatinib therapy. Cancer, 106:346–52.
Branford S, Cross NC, Hochhaus A, et al. 2006. Rationale for the rec-
ommendations for harmonizing current methodology for detecting 
BCR-ABL transcripts in patients with chronic myeloid leukaemia. 
Leukemia, 20:1925–30.
Branford S, Rudzki Z, Parkinson I, et al. 2004. Real-time quantitative PCR 
analysis can be used as a primary screen to identify patients with CML 
treated with imatinib who have BCR-ABL kinase domain mutations. 
Blood, 104:2926–32.
Branford S, Rudzki Z, Walsh S, et al. 2002. High frequency of point muta-
tions clustered within the adenosine triphosphate-binding region of 
BCR/ABL in patients with chronic myeloid leukaemia or Ph-positive 
acute lymphoblastic leukemia who develop imatinib (STI571) resis-
tance. Blood, 99:3472–5.Therapeutics and Clinical Risk Management 2008:4(1) 182
Henkes et al
Breccia M, Muscaritoli M, Aversa Z, et al. 2004. Imatinib Mesylate may 
improve fasting blood glucose in diabetic Ph+ Chronic Myelogenous 
Leukemia patients responsive to treatment. J Clin Oncol, 22:4653–5.
Buchdunger E, Zimmermann J, Mett H, et al. 1996. Inhibition of the Abl 
protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyri-
midine derivative. Cancer Res, 56:100–4.
Burchert A, Wang Y, Cai D, et al. 2005. Compensatory PI3-kinase/Akt/
mTor activation regulates imatinib resistance development. Leukemia, 
19:1774–82.
Burger H, van Tol H, Boersma AW, et al. 2004. Imatinib mesylate (STI571) 
is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 
drug pump. Blood, 104:2940–2.
Burgess MR, Skaggs BJ, Shah NP, et al. 2005. Comparative analysis of 
two clinically active BCR-ABL kinase inhibitors reveals the role 
of conformation-speciﬁ  c binding in resistance. Proc Natl Acad Sci, 
102:3395–400.
Buser CA, Furey B, Hoover R, et al. 2007. Contribution of the kinase 
cross-reactivity proﬁ  le of MK-0457 to clinical activity [abstract]. 
J Clin Oncol, 25:7050a.
Carpenter PA, Snyder DS, Flowers MED, et al. 2007. Prophylactic adminis-
tration of imatinib after hematopoietic cell transplantation for high-risk 
Philadelphia chromosome-positive leukemia. Blood, 109:2791–3.
Carter TA, Wodicka LM, Shah NP, et al. 2005. Inhibition of drug-resistant 
mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci, 
102:11011–6.
Cervantes F, Hernandez-Boluda JC, Steegmann JL, et al. 2003. Imatinib 
mesylate therapy of chronic phase chronic myeloid leukemia resistant 
or intolerant to interferon:results and prognostic factors for response 
and progression-free survival in 150 patients. Haematologica, 
88:1117–22.
Cheetham GM, Charlton PA, Golec JM, et al. 2007. Structural basis for 
potent inhibition of the Aurora kinases and a T315I multi-drug resist-
ant mutant form of Abl kinase by VX-680. Cancer Lett. Jan 18, (Epub 
ahead of print).
Choudhary DR, Mishra P, Kumar R, et al. 2006. Pregnancy on imatinib:
fatal outcome with meningocele. Ann Oncol, 17:178–9.
Chronic Myeloid Leukemia Trialists’ Collaborative Group. 1997. Interferon 
alfa versus chemotherapy for chronic myeloid leukemia:a meta-analysis 
of seven randomized trials. J Natl Cancer Inst, 89:1616–20.
Cohen MH, Williams G, Johnson JR, et al. 2002. Approval summary for 
imatinib mesylate capsules in the treatment of chronic myelogenous 
leukemia. Clin Cancer Res, 8:935–42.
Corbin AS, La Rosee P, Stoffregen EP, et al. 2003. Several Bcr-Abl kinase 
domain mutants associated with imatinib mesylate resistance remain 
sensitive to imatinib. Blood, 101:4611–4.
Cortes J, Giles F, O’Brien S, et al. 2003. Result of highdose imatinib 
mesylate in patients with Philadelphia chromosome-positive chronic 
myeloid leukemia after failure of interferon-alpha. Blood, 102:83–6.
Cortes J, O’Brien S, Verstovsek S, et al. 2004. Phase I Study of Lonafarnib 
(SCH66336) in Combination with Imatinib for Patients (Pts) with 
Chronic Myeloid Leukemia (CML) after Failure to Imatinib [abstract]. 
Blood, 104:1009.
Cortes J, Rousselot P, Kim DW, et al. 2007. Dasatinib induces complete 
hematologic and cytogenetic responses in patients with imatinib-
resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 
109:3207–13.
Cortes J. 2004. Natural history and staging of chronic myelogenous leuke-
mia. Hematol Oncol Clin North Am, 18:569–84.
Cortes J, Kantarjian HM, Baccarani M, et al. 2006. A phase 1/2 study of 
SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with 
Philadelphia Chromosome positive (Ph+) chronic myelogenous leuke-
mia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory 
or intolerant of imatinib [abstract]. Blood, 108:168a.
Cowan-Jacob SW, Guez V, Fendrich G, et al. 2004. Imatinib (STI571) 
resistance in chronic myelogenous leukemia:molecular basis of the 
underlying mechanisms and potential strategies for treatment. Mini 
Rev Med Chem, 4:285–99.
Craig AR, Kantarjian H, Cotes E, et al. 2007. A phase I study of INNO-406, a 
dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia 
chromosome positive (Ph+) chronic myelogenous leukemia (CML) or 
acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant 
of imatinib [abstract]. J Clin Oncol, 25:7046a.
Cross TJ, Bagot C, Portmann B, et al. 2006:Imatinib mesylate as a cause 
of acute liver failure. Am J Hematol, 81:189–92.
Dai Y, Rahmani M, Corey SJ, et al. 2004. A Bcr/Abl-independent, 
Lyn-dependent form of imatinib mesylate (STI-571) resistance 
is associated with altered expression of Bcl-2. J Biol Chem, 
279:34227–39.
DeAngelo DJ, Hochberg EP, Alyea EP, et al. 2004. Extended follow-up of 
patients treated with imatinib mesylate (Gleevec) for chronic myelog-
enous leukemia relapse after allogeneic transplantation:durable cytoge-
netic remission and conversion to complete donor chimerism without 
graft-versus-host disease. Clin Cancer Res, 10:5065–71.
de Groot JWB, Links TP and van der Graaf WTA. 2006. Tyrosine kinase 
inhibitors causing hypothyroidism in a patient on levothyroxine. Ann 
Oncol, 17:1719–20.
de Groot J, Zonnenberg B, Plukker W, et al. 2005. Imatinib induces 
hypothyroidism in patients receiving levothyroxine. Clin Pharmacol 
Ther, 78:433–8.
Deininger MW, Goldman JM, Lydon N, et al. 1997. The tyrosine kinase 
inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-
positive cells. Blood, 90:3691–8.
Deininger MW, O’Brien SG, Ford JM, et al. 2003. Practical management 
of patients with chronic myeloid leukemia receiving imatinib. J Clin 
Oncol, 21:1637–47.
Deininger MW, Schleuning M, Greinix H, et al. 2006. The effect of prior 
exposure to imatinib on transplant-related mortality. Haematologica, 
91:452–9.
Deininger MW. 2005. Chronic myeloid leukemia. Management of early 
stage disease. Hematology, 174–82.
Dengler J, von Bubnoff N, Decker T, et al. 2005. Combination of imat-
inib with rapamycin or RAD001 acts synergistically only in Bcr-
Abl-positive cells with moderate resistance to imatinib. Leukemia, 
19:1835–8.
Dewar AL, Farrugia AN, Condina MR, et al. 2006. Imatinib as a potential 
antiresorptive therapy for bone disease. Blood, 107:4334–7.
Dhalluin-Venier V, Besson C, Dimet S, et al. 2006. Imatinib mesylate-
induced acute hepatitis with autoimmune features. Eur J Gastroenterol 
Hepatol, 18:1235–7.
Donato NJ, Wu JY, Stapley J, et al. 2003. BCR-ABL independence and 
LYN kinase overexpression in chronic myelogenous leukemia cells 
selected for resistance to STI571. Blood, 101:690–8.
Druker BJ, Guilhot F, O’Brien SG, et al. 2006. Five-year follow-up of 
patients receiving imatinib for chronic myeloid leukemia. N Engl J 
Med, 355:2408–17.
Druker BJ, Talpaz M, Resta DJ, et al. 2001. Efﬁ  cacy and safety of a speciﬁ  c 
inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. 
N Engl J Med, 344:1031–7.
Druker BJ, Tamura S, Buchdunger E, et al. 1996. Effects of a selective 
inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive 
cells. Nat Med, 2:561–6.
Ebnoether M, Stentoft J, Ford J, et al. 2002. Cerebral oedema as a possible 
complication of treatment with imatinib. Lancet, 359:1751–2.
Faderl S, Talpaz M, Estrov Z, et al. 1999a. Chronic myelogenous leukemia:
biology and therapy. Ann Intern Med, 131:207–19.
Faderl S, Talpaz M, Estrov Z, et al. 1999b. The biology of chronic myeloid 
leukemia. N Engl J Med, 341:164–72.
Ferrero D, Pogliani EM, Rege-Cambrin G. 2006. Corticosteroids can 
reverse severe imatinib-induced hepatotoxicity. Haematologica, 
91:35–7.
Gambacorti C, Talpaz M, Sawyers C, et al. 2005. Five year follow-up 
results of a phase II trial in patients with late chronic phase chronic 
myeloid leukemia treated with Imatinib who are refractory/intolerant 
of Interferon-α [abstract]. Blood, 106:1089a.Therapeutics and Clinical Risk Management 2008:4(1) 183
Imatinib for chronic myeloid leukemia
Gambacorti-Passerini C, Brummendorf T, Kantarjian H, et al. 2007. Bosuti-
nib (SKI-606) exhibits clinical activity in patients with Philadelphia 
chromosome positive CML or ALL who failed imatinib [abstract]. 
J Clin Oncol, 25:7006a.
Gambacorti-Passerini C, Zucchetti M, Russo D, et al. 2003. Alpha1 acid 
glycoprotein binds to imatinib (STI571) and substantially alters its 
pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer 
Res, 9:625–32.
Gambacorti-Passerini C, Barni R, le Coutre P, et al. 2000. Role of alpha1 acid 
glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic 
cells to the abl inhibitor STI571. J Natl Cancer Inst, 92:1641–50.
Gambacorti-Passerini C, le Coutre P, Mologni L, et al. 1997. Inhibition of 
the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic 
cells and induces apoptosis. Blood Cells Mol Dis, 23:380–94.
Gardembas M, Rousselot P, Tulliez M, et al. 2003. Results of a prospective 
phase 2 study combining Imatinib Mesylate and Cytarabine for the 
treatment of Philadelphia-positive patients with chronic myelogenous 
leukemia in chronic phase. Blood, 102:4298–305.
Gardner ER, Burger H, van Schaik RH, et al. 2006. Association of enzyme 
and transporter genotypes with the pharmacokinetics of imatinib. Clin 
Pharmacol Ther, 80:192–201.
Giles F, le Coutre P, Bhalla K, et al. 2007a. A phase II study of nilotinib 
administered to patients with imatinib resistant or intolerant chronic 
myelogenous leukemia (CML) in chronic phase (CP), accelerated 
phase (AP) or blast crisis (BC) who also failed dasatinib [abstract]. 
J Clin Oncol, 25:7038a.
Giles F, Cortes J, Bergstrom DA, et al. 2006b. MK–0457, a novel Aurora 
Kinase and BCR-ABL inhibitor, is active against BCR-ABL T315I mutant 
Chronic Myelogenous Leukemia (CML) [abstract]. Blood, 108:163a.
Giles F, le Coutre P, Bhalla K, et al. 2006a. A phase II study of Nilotinib, a 
novel tyrosine kinase inhibitor administered to patients with Imatinib 
resistant or intolerant chronic myelogenous leukemia (CML) in chronic 
phase (CP), accelerated phase (AP) or blast crisis (BC) who have also 
failed Dasatinib therapy [abstract]. Blood, 108:2170a.
Giles FJ, Cortes J, Jones D, et al. 2007b. MK-0457, a novel kinase inhibitor, 
is active in patients with chronic myeloid leukemia or acute lymphocytic 
leukemia with the T315I BCR-ABL mutation. Blood, 109:500–2.
Giralt S, Arora M, Goldman JM et al. 2007. Impact of imatinib therapy on the 
use of allogeneic haematopoietic progenitor cell transplantation for the 
treatment of chronic myeloid leukaemia. Brit J Haematol, 137:461–7.
Gorre ME, Mohammed M, Ellwood K, et al. 2001. Clinical resistance to 
STI-571 cancer therapy caused by BCR-ABL gene mutation or ampli-
ﬁ  cation. Science, 293:876–80.
Gratwohl A, Schmid O, Baldomero H, et al. 2004. Haematopoietic stem 
cell transplantation (HSCT) in Europe 2002. Changes in indication and 
impact of team density. A report of the EBMT activity survey. Bone 
Marrow Transplant, 34:855–75.
Gratwohl A, Brand R, Apperley J, et al. 2006. Allogeneic hematopoietic 
SCT for chronic myeloid leukemia in Europe 2006:transplant activity, 
long-term data and current results. An analysis by the Chronic Leukemia 
Working Party of the European Group for Blood and Marrow Trans-
plantation (EBMT). Haematologica, 91:513–21.
Gratwohl A, Hermans J, Goldman JM, et al. 1998. Risk assessment for 
patients with chronic myeloid leukaemia before allogeneic blood or 
marrow transplantation. Chronic Leukemia Working Party of the 
European Group for Blood and Marrow Transplantation. Lancet, 
352:1087–92.
Grey A, O’Sullivan S, Reid IR, et al. 2006. Imatinib mesylate, increased 
bone formation, and secondary hyperparathyroidism. N Engl J Med, 
355:2494–5.
Griswold IJ, MacPartlin M, Bumm T, et al. 2006. Kinase domain mutants 
of Bcr-Abl exhibit altered transformation potency, kinase activity, and 
substrate utilization, irrespective of sensitivity to imatinib. Mol Cell 
Biol, 26:6082–93.
Gschwind HP, Pfaar U, Waldmeier F, et al. 2005. Metabolism and disposi-
tion of imatinib mesylate in healthy volunteers. Drug Metab Dispos, 
33:1503–12.
Guglielmi C, Arcese W, Dazzi F, et al. 2002. Donor lymphocyte infusion 
for relapsed chronic myelogenous leukemia:prognostic relevance of 
the initial cell dose. Blood, 100:397–405.
Guilhot F, Apperley J, Kim DW, et al. 2007. Dasatinib induces signiﬁ  cant 
hematologic and cytogenetic responses in patients with imatinib-resistant 
or -intolerant chronic myeloid leukemia in accelerated phase. Blood, Jan 
30, (Epub ahead of print).
Guilhot F, Chastang C, Michallet M, et al. 1997. Interferon alfa-2b combined 
with cytarabine versus interferon alone in chronic myelogenous 
leukemia. French Chronic Myeloid Leukemia Study Group. N Engl 
J Med, 337:223–9.
Gumireddy K, Baker SJ, Cosenza SC, et al. 2005. A non-ATP-competitive 
inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad 
Sci USA, 102:1992–7.
Hamberg F, de Jong FA, Boonstra JG, et al. 2006. Non-islet-cell tumor induced 
hypoglycemia in patients with advanced Gastrointestinal Stromal Tumor 
possibly worsened by Imatinib. J Clin Oncol, 24:e30–e31.
Hardan I, Amariglio N, Trakhtenbrot L, et al. 2006. Towards stopping Imatinib 
therapy under the umbrella of Interferone:Alpha-Interferone improves 
molecular response in CML patients with Imatinib induced complete 
cytogenetic remission:An early observation from a study of pegylated 
Interferone in the setup of minimal residual disease. Blood, 108:4788a.
Harrington EA, Bebbington D, Moore J, et al. 2004. VX-680, a potent and 
selective small-molecule inhibitor of the Aurora kinases, suppresses 
tumor growth in vivo. Nat Med, 10:262–7.
Hasford J, Pﬁ  rrmann M, Hehlmann R, et al. 1998. A new prognostic score 
for survival of patients with chronic myeloid leukemia treated with 
interferon alfa. Writing Committee for the Collaborative CML Prog-
nostic Factors Project Group. J Natl Cancer Inst, 90:850–8.
Hehlmann R, Berger U, Hochhaus A. 2005. Chronic myeloid leukemia:a 
model for oncology. Ann Hematol, 84:487–97.
Hehlmann R, Berger U, Pﬁ  rrmann M, et al. 2007. Drug treatment is superior 
to allografting as ﬁ  rst line therapy in chronic myeloid leukemia. Blood, 
Feb 22, (Epub ahead of print).
Hehlmann R, Heimpel H, Hasford J, et al. 1993. Randomized comparison 
of busulfan and hydroxyurea in chronic myelogenous leukemia:pro-
longation of survival by hydroxyurea. The German CML Study Group. 
Blood, 82:398–407.
Hehlmann R, Heimpel H, Hasford J, et al. 1994. Randomized com-
parison of interferon-alpha with busulfan and hydroxyurea in chronic 
myelogenous leukemia. The German CML Study Group. Blood, 
84:4064–77.
Hochhaus A, Kantarjian HM, Baccarani M, et al. 2007. Dasatinib induces 
notable hematologic and cytogenetic responses in chronic-phase chronic 
myeloid leukemia after failure of imatinib therapy. Blood, 109:2303–9.
Hochhaus A, Kim DW, Rousselot P, et al. 2006. Dasatinib (SPRYCEL®) 50 
mg or 70 mg BID versus 100 mg or 140 mg QD in patients with chronic 
myeloid leukemia in chronic phase (CML-CP) resistant or intolerant to 
Imatinib: Results of the CA180-034 Study [abstract]. Blood, 108:166a.
Hochhaus A, Kreil S, Corbin AS, et al. 2002. Molecular and chromosomal 
mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 
16:2190–6.
Hochhaus A, Lin F, Reiter A, et al. 1995. Variable numbers of BCR-ABL 
transcripts persist in CML patients who achieve complete cytogenetic 
remission with interferon-alpha. Br J Haematol, 9:126–31.
Hochhaus A, Lin F, Reiter A, et al. 1996. Quantiﬁ  cation of residual disease 
in chronic myelogenous leukemia patients on interferon-alpha therapy 
by competitive polymerase chain reaction. Blood, 87:1549–55.
Hochhaus A, Reiter A, Saussele S, et al. 2000. Molecular heterogeneity 
in complete cytogenetic responders after interferon-alpha therapy for 
chronic myelogenous leukemia:low levels of minimal residual disease 
are associated with continuing remission. German CML Study Group 
and the UK MRC CML Study Group. Blood, 95:62–6.
Hofmann WK, Komor M, Wassmann B, et al. 2003. Presence of 
the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) 
treatment in patients with Ph+ acute lymphoblastic leukemia. Blood, 
102:659–61.Therapeutics and Clinical Risk Management 2008:4(1) 184
Henkes et al
Hoover RR, Mahon FX, Melo JV, et al. 2002. Overcoming STI571 
resistance with the farnesyl transferase inhibitor SCH66336. Blood, 
100:1068–71.
Houghton PJ, Germain GS, Harwood FC, et al. 2004. Imatinib mesylate is a 
potent inhibitor of the ABCG2 (BCRP) transporter and reverses resist-
ance to topotecan and SN-38 in vitro. Cancer Res, 64:2333–7.
Hsiao LT, Chung HM, Lin JT, et al. 2002. Stevens-Johnson syndrome after 
treatment with STI571: A case report. Br J Haematol, 117:620–2.
Hu Y, Liu Y, Pelletier S, et al. 2004. Requirement of Src kinases Lyn, Hck 
and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not 
chronic myeloid leukemia. Nat Genet, 36:453–61.
Hughes T, Branford S, Reynolds J, et al. 2004. Higher dose Imatinib 
(600 mg/day) with selective intensiﬁ  cation in newly diagnosed CML 
patients in chronic phase:cytogenetic response rates at 12 months are 
superior to IRIS [abstract]. Blood, 104:1001a.
Hughes T, Deininger M, Hochhaus A, et al. 2006. Monitoring CML patients 
responding to treatment with tyrosine kinase inhibitors:review and 
recommendations for harmonizing current methodology for detecting 
BCR-ABL transcripts and kinase domain mutations and for expressing 
results. Blood, 108:28–37.
Hughes T. 2006. ABL Kinase inhibitor therapy for CML:baseline assess-
ments and response monitoring. Hematology:211–17.
Hughes TP, Branford S, Reynolds J, et al. 2005. Maintenance of Imatinib dose 
intensity in the ﬁ  rst six months of therapy for newly diagnosed patients 
with CML is predictive of molecular response, independent of the ability 
to increase dose at a later point [abstract]. Blood, 106:164a.
Hughes TP, Kaeda J, Branford S, et al. 2003. Frequency of major molecular 
responses to imatinib or interferon alfa plus cytarabine in newly diag-
nosed chronic myeloid leukemia. N Engl J Med, 349:1423–32.
Illmer T, Schaich M, Platzbecker U, et al. 2004. P-glycoprotein-mediated 
drug efﬂ  ux is a resistance mechanism of chronic myelogenous leukemia 
cells to treatment with imatinib mesylate. Leukemia, 18:401–8.
Inokuchi K. 2006. Chronic myelogenous leukemia:from molecular biol-
ogy to clinical aspects and novel targeted therapies. J Nippon Med 
Sch, 73:178–92.
Issa JP, Gharibyan V, Cortes J, et al. 2005. Phase II study of low-dose 
decitabine in patients with chronic myelogenous leukemia resistant to 
imatinib mesylate. J Clin Oncol, 23:3948–56.
Issaad C, Ahmed M, Novault S, et al. 2000. Biological effects induced by 
variable levels of BCR-ABL protein in the pluripotent hematopoietic 
cell line UT-7. Leukemia, 14:662–70.
Isshiki I, Yamaguchi K, Okamoto S. 2004. Interstitial pneumonitis during 
imatinib therapy. Br J Haematol, 125:420.
Jayson GC, Parker GJ, Mullamitha S, et al. 2005. Blockade of platelet-
derived growth factor receptor-beta by CDP860, a humanized, 
PEGylated di-Fab’, leads to ﬂ  uid accumulation and is associated with 
increased tumor vascularized volume. J Clin Oncol, 23:973–81.
Jabbour E, le Coutre P, Baccarani M, et al. 2007. Nilotinib is associated 
with minimal cross intolerance to imatinib in patients with imatinib-
intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) 
[abstract]. J Clin Oncol, 25:7039a.
Joensuu H, Reichardt P. 2006. Correspondence:Imatinib and Altered Bone 
and Mineral Metabolism. N Engl J Med, 355:628.
Jonuleit T, Peschel C, Schwab R, et al. 1998. Bcr-Abl kinase promotes cell 
cycle entry of primary myeloid CML cells in the absence of growth 
factors. Br J Haematol, 100:295–303.
Jonuleit T, van der Kuip H, Miething C, et al. 2000. Bcr-Abl kinase down-
regulates cyclin-dependent kinase inhibitor p27 in human and murine 
cell lines. Blood, 96:1933–9.
Jorgensen HG, Allan EK, Graham SM, et al. 2005. Lonafarnib reduces the 
resistance of primitive quiescent CML cells to imatinib mesylate in 
vitro. Leukemia, 19:1184–91.
Kantarjian H, Cortes J, O’Brien S, et al. 2004a. Long-term survival beneﬁ  t 
and improved complete cytogenetic and molecular response rates with 
imatinib mesylate in Philadelphia chromosome-positive chronic-phase 
chronic myeloid leukemia after failure of interferon alpha. Blood, 
104:1979–88.
Kantarjian H, Giles F, Wunderle L, et al. 2006a. Nilotinib in imatinib-
resistant CML and Philadelphia chromosome-positive ALL. N Engl 
J Med, 354:2542–51.
Kantarjian H, O’Brien S, Talpaz M, et al. 2007b. Outcome of patients with 
Philadelphia chromosome-positive chronic myelogenous leukemia 
post-imatinib mesylate failure. Cancer, 109:1556–60.
Kantarjian H, Pasquini R, Hamerschlak N, et al. 2007a. Dasatinib or high-
dose imatinib for chronic-phase chronic myeloid leukemia after failure 
of ﬁ  rst-line imatinib:a randomized phase-II trial. Blood, Feb 22, (Epub 
ahead of print).
Kantarjian H, Sawyers C, Hochhaus A, et al. 2002a. Hematologic and 
cytogenetic responses to imatinib mesylate in chronic myelogenous 
leukemia. N Engl J Med, 346:645–52.
Kantarjian H, Talpaz M, O’Brien S, et al. 2002b. Imatinib mesylate for Philadel-
phia chromosome-positive, chronic-phase myeloid leukemia after failure 
of interferon-alpha:follow-up results. Clin Cancer Res, 8:2177–87.
Kantarjian H, Talpaz M, O’Brien S, et al. 2003a. Dose escalation of imatinib 
mesylate can overcome resistance to standard-dose therapy in patients 
with chronic myelogenous leukemia. Blood, 101:473–5.
Kantarjian H, Talpaz M, O’Brien S, et al. 2004b. High-dose imatinib 
mesylate therapy in newly diagnosed Philadelphia chromosome-positive 
chronic phase chronic myeloid leukemia. Blood, 103:2873–8.
Kantarjian HM, Gattermann N, Hochhaus A, et al. 2006b. A phase II study 
of Nilotinib a novel tyrosine kinase Inhibitor administered to Imatinib-
resisbtant or intolerant patients with chronic myelogenous leukemia 
(CML) in accelerated phase (AP) [abstract]. Blood, 108:2169a.
Kantarjian HM, O’Brien S, Cortes JE, et al. 2002c. Imatinib mesylate therapy 
for relapse after allogeneic SCT for chronic myelogenous leukemia. 
Blood, 100:1590–5.
Kantarjian HM, O’Brien S, Cortes J, et al. 2003b. Results of decitabine 
(5-aza-2’deoxycytidine) therapy in 130 patients with chronic 
myelogenous leukemia. Cancer, 98:522–8.
Kantarjian HM, O’Brien S, Smith TL. 1999. Treatment of philadelphia chro-
mosome-positive early chronic phase chronic myelogenous leukemia 
with daily doses of interferon alpha and low-dose cytarabine. J Clin 
Oncol, 17:284–92.
Keeshan K, Mills KI, Cotter TG, et al. 2001. McKenna SL. Elevated Bcr-Abl 
expression levels are sufﬁ  cient for a haematopoietic cell line to acquire 
a drug-resistant phenotype. Leukemia, 15:1823–33.
Kerkela R, Grazette L, Yacobi R, et al. 2006. Cardiotoxicity of the cancer 
therapeutic agent imatinib mesylate. Nat Med, 12:908–16.
Kim DW, Chung YJ, Lee S, et al. 2004. Pretransplant Imatinib can improve 
the outcome of non myeloablative SCT without increasing the mortal-
ity in Philadelphia-chromosome positive chronic myeloid leukemia. 
Leukemia, 18:1907–9.
Kluin-Nelemans HC, Buck G, le Cessie S, et al. 2004. Randomized com-
parison of low-dose versus high-dose interferon-alfa in chronic myeloid 
leukemia: prospective collaboration of 3 joint trials by the MRC and 
HOVON groups. Blood, 103:4408–15.
Koleske AJ, Gifford AM, Scott ML, et al. 1998. Essential roles for the Abl 
and Arg tyrosine kinases in neurulation. Neuron, 21:1259–72.
Kuhr T, Burgstaller S, Apfelbeck U, et al. 2003. A randomized study compar-
ing interferon (IFN alpha) plus low-dose cytarabine and interferon plus 
hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia 
(CML). Leuk Res, 27:405–11.
Kuwano Y, Asahina A, Watanabe R, et al. 2006. Heliotrope-like eruption 
mimicking dermatomyositis in a patient treated with imatinib mesylate 
for chronic myeloid leukemia. Int J Dermatol, 45:1249–51.
Larson RA, Druker BJ, Guilhot F, et al. 2006. Correlation of pharma-
cokinetic data with cytogenetic and molecular response in newly 
diagnosed patients with chronic myeloid leukemia in chronic phase 
(CML-CP) treated with Imatinib – an analysis of IRIS study data. 
Blood, 108:429a.
le Coutre P, Bhalla K, Giles G, et al. 2007. A phase II study of nilotinib 
administered to imatinib resistant and intolerant patients with chronic 
myelogenous leukenia (CML) in chronic phase (CP) [abstract]. J Clin 
Oncol, 25:7007a.Therapeutics and Clinical Risk Management 2008:4(1) 185
Imatinib for chronic myeloid leukemia
le Coutre P, Kreuzer KA, Na IK, et al. 2002. Determination of alpha-1 acid 
glycoprotein in patients with Ph+ chronic myeloid leukemia during the 
ﬁ  rst 13 weeks of therapy with STI571. Blood Cells Mol Dis, 28:75–85.
le Coutre P, Tassi E, Varella-Garcia M, et al. 2000. Induction of resistance 
to the Abelson inhibitor STI571 in human leukemic cells through gene 
ampliﬁ  cation. Blood, 95:1758–66.
Lee SJ. 2000. Chronic myelogenous leukaemia. Br J Haematol, 
111:993–1009.
Lin NU, Sarantopoulos S, Stone JR, et al. 2003. Fatal hepatic necrosis fol-
lowing imatinib mesylate therapy. Blood, 102:3455–6.
Lindahl P, Johansson BR, Leveen P, et al. 1997. Pericyte loss and microan-
eurysm formation in PDGF-B-deﬁ  cient mice. Science, 277:242–5.
Lionberger JM, Wilson MB, Smithgall TE. 2000. Transformation of myeloid 
leukemia cells to cytokine independence by Bcr-Abl is suppressed by 
kinase-defective Hck. J Biol Chem, 275:18581–5.
Ly C, Arechiga AF, Melo JV, et al. 2003. Bcr-Abl kinase modulates the 
translation regulators ribosomal protein S6 and 4E-BP1 in chronic 
myelogenous leukemia cells via the mammalian target of rapamycin. 
Cancer Res, 63:5716–22.
Ma CX, Hobday TJ, Jett JR. 2003. Imatinib mesylate-induced interstitial 
pneumonits. Mayo Clin Proc, 78:1578–9.
Mahon FX, Deininger MW, Schultheis B, et al. 2000. Chabrol J, Reiffers J, 
Goldman JM, Melo JV. Selection and characterization of BCR-ABL pos-
itive cell lines with differential sensitivity to the tyrosine kinase inhibitor 
STI571:diverse mechanisms of resistance. Blood, 96:1070–9.
Marin D, Marktel S, Foot N, et al. 2003. Granulocyte colony-stimulation 
factor reverses cytopenia and may permit cytogenetic responses in 
patients with chronic myeloid leukemia treated with imatinib mesylate. 
Haematologica, 88:227–9.
Martin JM, Jorda E, Monteagudo C, et al. 2006. Follicular acneiform 
eruption induced by imatinib. J Eur Acad Dermatol Venereol, 
20:1368–70.
Martinelli G, Soverini S, Iacobucci I, et al. 2007. MK-0457:a light at the 
end of the tunnel ? Blood, 109:396–7.
Matthews N, Visintin C, Hartzoulakis B, et al. 2006. Aurora A and B 
kinases as targets for cancer:will they be selective for tumors? Expert 
Rev Anticancer Ther, 6:109–20.
Medeiros BC, Lipton JH. 2006. Chlordiazepoxide for imatinib-induced 
muscular cramps. Eur J Haematol, 77:538.
Michallet M, Maloisel F, Delain M, et al. 2004. Pegylated recombinant 
interferon alpha-2b vs recombinant interferon alpha-2b for the initial 
treatment of chronic-phase chronic myelogenous leukemia:a phase III 
study. Leukemia, 18:309–15.
Mohi MG, Boulton C, Gu TL, et al. 2004. Combination of rapamycin and 
protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias 
caused by oncogenic PTKs. Proc Natl Acad Sci USA, 101:3130–5.
Muller MC, Lahaye T, Hochhaus A. 2002. Resistance to tumor speciﬁ  c 
therapy with imatinib by clonal selection of mutated cells. Dtsch Med 
Wochenschr, 127:2205–7.
Nagar B, Bornmann WG, Pellicena P, et al. 2002. Crystal structures of the 
kinase domain of c-Abl in complex with the small molecule inhibitors 
PD173955 and imatinib (STI-571). Cancer Res, 62:4236–43.
Nakanishi T, Shiozawa K, Hassel BA, et al. 2006. Complex interaction of 
BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells:BCRP-
mediated resistance to imatinib is attenuated by imatinib-induced 
reduction of BCRP expression. Blood, 108:678–84.
Nguyen TT, Mohrbacher AF, Tsai YC, et al. 2000. Quantitative measure of 
c-abl and p15 methylation in chronic myelogenous leukemia:biological 
implications. Blood, 95:2990–2.
Nowell PC, Hungerford DA. 1960. Chromosome studies on normal and 
leukemic human leukocytes. J Natl Cancer Inst, 25:85–109.
O´Hare T, Eide CE, Deininger MWN. 2007. Bcr-Abl Kinase domain 
mutations, drug resistance and the road to a cure of chronic myeloid 
leukemia. Blood, May 11, (Epub ahead of print).
O’Hare T, Walters DK, Stoffregen EP, et al. 2005. In vitro activity of Bcr-Abl 
inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-
resistant Abl kinase domain mutants. Cancer Res, 65:4500–5.
O’Brien S, Kantarjian H, Talpaz M. 1996. Practical guidelines for the 
management of chronic myelogenous leukemia with interferon alpha. 
Leuk Lymphoma, 23:247–52.
O’Brien SG, Guilhot F, Larson RA, et al. 2003. Imatinib compared with 
interferon and low-dose cytarabine for newly diagnosed chronic-phase 
chronic myeloid leukemia. N Engl J Med, 348:994–1004.
Oehler VG, Gooley T, Snyder DS, et al. 2007. The effects of imatinib 
mesylate treatment before allogeneic transplantation for chronic 
myeloid leukemia. Blood, 109:1782–89.
Oetzel C, Jonuleit T, Gotz A, et al. 2000. The tyrosine kinase inhibitor 
CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells 
by down-regulating BCL-X. Clin Cancer Res, 6:1958–68.
Ohnishi K, Sakai F, Kudoh S, et al. 2006. Twenty-seven cases of drug-
induced interstitial lung disease associated with imatinib mesylate. 
Leukemia, 20:1162–4.
Ohyashiki K, Kuriyama Y, Nakajima A, et al. 2002. Imatinib mesylate-
induced hepato-toxicity in chronic myeloid leukemia demonstrated focal 
necrosis resembling acute viral hepatitis. Leukemia, 16:2160–1.
Oki Y, Kantarjian HM, Gharibyan V, et al. 2007. Phase II study of low-
dose decitabine in combination with imatinib mesylate in patients with 
accelerated or myeloid blastic phase of chronic myelogenous leukemia. 
Cancer, 109:899–906.
Olavarria E, Ottmann OG, Deininger M, et al. 2003. Response to imatinib 
in patients who relapse after allogeneic stem cell transplantation for 
chronic myeloid leukemia. Leukemia, 17:1707–12.
Ottmann O, Kantarjian HM, Larson R, et al. 2006. A phase II study of 
Nilotinib, a novel tyrosine kinase inhibitor administered to Imatinib 
resistant or intolerant patients with chronic myelogenous leukemia 
(CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lympho-
blastic leukemia (ALL) [abstract]. Blood, 108:1862a.
Owen S, Hatﬁ  eld A, Letvak L. 2006. Correspondence:Imatinib and Altered 
Bone and Mineral Metabolism. N Engl J Med, 355:627.
Ozvegy-Laczka C, Hegedus T, Varady G, et al. 2004. High-afﬁ  nity interac-
tion of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. 
Mol Pharmacol, 65:1485–95.
Passweg JR, Walker I, Sobocinski KA, et al. 2004. Validation and extension 
of the EBMT Risk Score for patients with chronic myeloid leukaemia 
receiving allogeneic haematopoietic stem cell transplants. Br J Hae-
matol, 125:613–20.
Pavithran K, Thomas M. 2005. Imatinib induced Stevens-Johnson syndrome:
lack of recurrence following re-challenge with a lower dose. Indian J 
Dermatol Venereol Leprol, 71:288–9.
Peng B, Hayes M, Resta D, et al. 2004. Pharmacokinetics and pharmaco-
dynamics of imatinib in a phase I trial with chronic myeloid leukemia 
patients. J Clin Oncol, 22:935–42.
Peng B, Lloyd P, Schran H. 2005. Clinical pharmacokinetics of imatinib. 
Clin Pharmacokinet, 44:879–94.
Peters DG, Hoover RR, Gerlach MJ, et al. 2001. Activity of the farnesyl 
protein transferase inhibitor SCH66336 against BCR/ABL-induced 
murine leukemia and primary cells from patients with chronic myeloid 
leukemia. Blood, 97:1404–12.
Petzer AL, Eaves CJ, Lansdorp PM, et al. 1996. Characterization of primitive 
subpopulations of normal and leukemic cells present in the blood of 
patients with newly diagnosed as well as established chronic myeloid 
leukemia. Blood, 88:2162–71.
Pfeifer H, Wassmann B, Pavlova A, et al. 2007. Kinase domain mutations 
of BCR-ABL frequently precede imatinib-based therapy and give 
rise to relapse in patients with de novo Philadelphia-positive acute 
lymphoblastic leukemia (Ph+ ALL). Blood, Apr 3, (Epub ahead of 
print).
Picard S, Titier K, Etienne G, et al. 2007. Trough imatinib plasma lev-
els are associated with both cytogenetic and molecular responses 
to standard-dose imatinib in chronic myeloid leukemia. Blood, 
109:3496–9.
Pilot PR, Sablinska K, Owen S, et al. 2006. Epidemiological analysis of 
second primary malignancies in more than 9500 patients treated with 
imatinib. Leukemia, 20:148.Therapeutics and Clinical Risk Management 2008:4(1) 186
Henkes et al
Popescu LM, Vidulescu C, Curici A, et al. 2006. Imatinib inhibits spon-
taneous rhythmic contractions of human uterus and intestine. Eur J 
Pharmacol, 546:177–81.
Prabhash K, Sastry PS, Biswas G, et al. 2005. Pregnancy outcome of two 
patients treated with imatinib. Ann Oncol, 16:1983–4.
Ptasznik A, Nakata Y, Kalota A, et al. 2004. Emerson SG, Gewirtz AM. 
Short interfering RNA (siRNA) targeting the Lyn kinase induces 
apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia 
cells. Nat Med, 10:1187–9.
Pye S, Cortes J, Rosti G, et al. 2006. Imatinib and Pregnancy [abstract]. 
Blood, 108:431a.
Radich JP, Gooley T, Bensinger W, et al. 2003. HLA-matched related hemat-
opoietic cell transplantation for chronic-phase CML using a targeted 
busulfan and cyclophosphamide preparative regimen. Blood, 102:31–5.
Ray A, Cowan-Jacob SW, Manley P, et al. 2007. Identiﬁ  cation of Bcr-
Abl point mutations conferring resistance to the Abl kinase inhibitor 
AMN107 (nilotinib) by a random mutagenesis study. Blood, Feb 15, 
(Epub ahead of print).
Robert C, Soria JC, Spatz A, et al. 2005. Cutaneous side-effects of kinase 
inhibitors and blocking antibodies. Lancet Oncology, 6:491–500.
Roche-Lestienne C, Soenen-Cornu V, Grardel-Duﬂ  os N, et al. 2002. Several 
types of mutations of the Abl gene can be found in chronic myeloid 
leukemia patients resistant to STI571, and they can pre-exist to the 
onset of treatment. Blood, 100:1014–8.
Rosado MF, Donna E, Ahn YS. 2003. Challenging problems in advanced 
malignancy:case 3. Imatinib mesylate-induced interstitial pneumonitis. 
J Clin Oncol, 21:3171–3.
Rosti G, Martinelli G, Bassi S, et al. 2004. Molecular response to imatinib in 
late chronic phase chronic myeloid leukemia. Blood, 103:2284–90.
Rowley JD. 1973. Letter:A new consistent chromosomal abnormality in 
chronic myelogenous leukaemia identiﬁ  ed by quinacrine ﬂ  uorescence 
and Giemsa staining. Nature, 243:290–3.
Roy L, Guilhot J, Krahnke T, et al. 2006. Survival advantage from imatinib 
compared with the combination interferon alpha plus cytarabine in 
chronic-phase chronic myelogenous leukemia:historical comparison 
between two phase 3 trials. Blood, 108:1478–84.
Roy L, Guilhot J, Martineau G, et al. 2005. Unexpected occurrence of 
second malignancies in patients treated with interferon followed by 
imatinib mesylate for chronic myelogenous leukemia. Leukemia, 
19:1689–92.
Rule SA, O’Brien SG, Crossman LC. 2002. Managing cutaneous reactions 
to imatinib therapy. Blood, 100:3434–5.
Sacchi S, Kantarjian H, O’Brien S, et al. 1995. Immune-mediated and 
unusual complications during interferon alfa therapy in chronic myel-
ogenous leukemia. J Clin Oncol, 13:2401–7.
Samanta AK, Lin H, Sun T, et al. 2006. Janus kinase 2:a critical target in 
chronic myelogenous leukemia. Cancer Res, 66:6468–72.
Sanchez-Gonzalez B, Pascual-Ramirez JC, Fernandez-Abellan P, et al. 2003. 
Severe skin reaction to imatinib in a case of Philadelphia-positive acute 
lymphoblastic leukemia. Blood, 101:2446.
Sawyers CL, Callahan W, Witte ON. 1992. Dominant negative MYC blocks 
transformation by ABL oncogenes. Cell, 70:901–10.
Sawyers CL, Hochhaus A, Feldman E, et al. 2002. Imatinib induces hematologic 
and cytogenetic responses in patients with chronic myelogenous leukemia 
in myeloid blast crisis:results of a phase 2 study. Blood, 99:3530–9.
Sawyers CL. 1999. Chronic myeloid leukemia. N Engl J Med, 340:1330–40.
Scheinfeld N. 2006. Imatinib mesylate and dermatopathy part 2:a review 
of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol, 
5:228–31.
Schellings MW, Lowenberg B, Pinto YM, et al. 2007. Another Look at 
Imatinib Mesylate. New Engl J of Med, 356:1183.
Schindler T, Bornmann W, Pellicena P, et al. 2000. Structural mecha-
nism for STI-571 inhibition of abelson tyrosine kinase. Science, 
289:1938–42.
Schmidli H, Peng B, Riviere GJ, et al. 2005. Population pharmacokinetics of 
imatinib mesylate in patients with chronic-phase chronic myeloid leu-
kaemia:results of a phase III study. Br J Clin Pharmacol, 60:35–44.
Schwartzberg PL, Stall AM, Hardin JD, et al. 1991. Mice homozygous for 
the ablm1 mutation show poor viability and depletion of selected B and 
T cell populations. Cell, 65:1165–75.
Seymour JF, Grigg A, Reynolds J, et al. 2006. Two year data from a pro-
spective safety study analyzing the consequences of Imatinib Mesylate 
inhibition of sensitive kinases other than bcr-abl in patients with previ-
ously untreated chronic phase CML [abstract]. Blood, 108:2147a.
Shah NP, Nicoll JM, Nagar B, et al. 2002. Multiple BCR-ABL kinase 
domain mutations confer polyclonal resistance to the tyrosine kinase 
inhibitor imatinib (STI571) in chronic phase and blast crisis chronic 
myeloid leukemia. Cancer Cell, 2:117–25.
Shah NP, Tran C, Lee FY, et al. 2004. Overriding imatinib resistance with 
a novel ABL kinase inhibitor. Science, 305:399–401.
Shah NP, Skaggs B, Branford S, et al. 2006a. Sequential kinase inhibitor 
iherapy in CML patients can select for cells harboring compound 
BCR-ABL kinase domain mutations with increased oncogenic potency:
Rationale for early combination therapy of ABL kinase inhibitors 
[abstract]. Blood, 108:751a.
Shah NP, Skaggs B, Branford S, et al. 2006b. The most common Dasatinib-
resistant BCR-ABL kinase domain mutations in patients with Chronic 
Myeloid Leukemia are sensitive to VX-680:Rationale for early combi-
nation kinase inhibitor therapy [abstract]. Blood, 108:2175a.
Shimoni A, Kröger N, Zander AR, et al. 2003. Imatinib mesylate (STI571) 
in preparation for allogeneic hematopoietic SCT and donor lymphocyte 
infusions in patients with Philadelphia-positive acute leukemias. Leu-
kemia, 17:290–7.
Silver RT, Peterson BL, Szatrowski TP, et al. 2003. Treatment of the chronic 
phase of chronic myeloid leukemia with an intermittent schedule of 
recombinant interferon alfa-2b and cytarabine:results from CALGB 
study 9013. Leuk Lymphoma, 44:39–48.
Silver RT, Talpaz M, Sawyers CL, et al. 2004. Four years of follow-up of 
1027 patients with late chronic phase, accelerated phase, or blast crisis 
chronic myeloid leukemia treated with Imatinib in three large phase II 
trials [abstract]. Blood, 104:23a.
Silver RT, Woolf SH, Hehlmann R, et al. 1999. An evidence-based analysis of 
the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow 
transplantation in treating the chronic phase of chronic myeloid leukemia: 
developed for the American Society of Hematology. Blood, 94:1517–36.
Skaggs BJ, Gorre ME, Ryvkin A, et al. 2006. Phosphorylation of the ATP-
binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. 
Proc Natl Acad Sci USA, 103:19466–71.
Sokal JE, Cox EB, Baccarani M, et al. 1984. Prognostic discrimination in 
good-risk chronic granulocytic leukemia. Blood, 63:789–99.
Soverini S, Tasco G, Grafone T, et al. 2007. Binding mode of the tyrosine 
kinase inhibitor bosutinib (SKI-606) to Abl kinase [abstract]. J Clin 
Oncol, 25:7049a.
Soverini S, Colarossi S, Gnani A, et al. 2006. Contribution of ABL 
kinase domain mutations to imatinib resistance in different subsets of 
Philadelphia-positive patients:by the GIMEMA Working Party on Chronic 
Myeloid Leukemia. Clin Cancer Res, 12:7374–9.
Stylian A, Fennely ET, Butler JP, et al. 2006. Allogeneic transplant out-
comes in Imatinib-refractory chronic myeloid leukaemia (CML) are 
similar to transplant outcomes in Imatinib-responsive / Imatinib-naive 
CML and appear to be predicted by the EBMT risk score [abstract]. 
Blood, 108:3155a.
Suppiah R, Kalaycio M. 2006. Successful outcome of pregnancy in a patient 
with chronic myelogenous leukemia exposed to imatinib during the ﬁ  rst 
trimester. Leuk Lymphoma, 47:1149–50.
Talpaz M, Kantarjian H, Kurzrock R, et al. 1991. Interferon-alpha produces 
sustained cytogenetic responses in chronic myelogenous leukemia. Phil-
adelphia chromosome-positive patients. Ann Intern Med, 114:532–8.
Talpaz M, Kantarjian HM, McCredie KB, et al. 1986. Hematologic remission 
and cytogenetic improvement induced by recombinant human interferon-α 
in chronic myelogenous leukemia. N Engl J Med, 314:1065–9.
Talpaz M, McCredie KB, Mavligit GM, et al. 1983. Leukocyte interferon-
induced myeloid cytoreduction in chronic myelogenous leukemia. 
Blood, 62:689–92.Therapeutics and Clinical Risk Management 2008:4(1) 187
Imatinib for chronic myeloid leukemia
Talpaz M, Shah NP, Kantarjian H, et al. 2006. Dasatinib in imatinib-
resistant Philadelphia chromosome-positive leukemias. N Engl J Med, 
354:2531–41.
Talpaz M, Silver RT, Druker BJ, et al. 2002. Imatinib induces durable 
hematologic and cytogenetic responses in patients with accelerated 
phase chronic myeloid leukemia:results of a phase 2 study. Blood, 
99:1928–37.
The Benelux CML Study Group. 1998. Randomized Study on Hydroxyurea 
alone versus Hydroxyurea combined with low-dose Interferon-2b for 
Chronic Myeloid Leukemia. Blood, 91:2713–21.
Thomas J, Wang L, Clark RE, et al. 2004. Active transport of imat-
inib into and out of cells:implications for drug resistance. Blood, 
104:3739–45.
Tokarski JS, Newitt JA, Chang CY, et al. 2006. The structure of Dasatinib 
(BMS-354825) bound to activated ABL kinase domain elucidates its 
inhibitory activity against imatinib-resistant ABL mutants. Cancer 
Res, 66:5790–7.
van der Kuip H, Moehring A, Wohlbold L, et al. 2004. Imatinib mesylate 
(STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic 
cell lines. Leuk Res, 28:405–8.
van der Kuip H, Wohlbold L, Oetzel C, et al. 2005. Mechanisms of clinical 
resistance to small molecule tyrosine kinase inhibitors targeting onco-
genic tyrosine kinases. Am J Pharmacogenomics, 5:101–12.
Vardiman JW, Harris NL, Brunning RD. 2002. The World Health 
Organization (WHO) classiﬁ  cation of the myeloid neoplasms. Blood, 
100:2292–302.
Vidal D, Puig L, Sureda A, et al. 2002. STI571-Induced Stevens-Johnson 
syndrome. Br J Haematol, 119:274–5.
von Bubnoff N, Schneller F, Peschel C, et al. 2002. BCR-ABL gene mutations 
in relation to clinical resistance of Philadelphia-chromosome-positive 
leukaemia to STI571: a prospective study. Lancet, 359:487–91.
von Bubnoff N, Veach DR, van der Kuip H, et al. 2005. A cell-based screen 
for resistance of Bcr-Abl-positive leukemia identiﬁ  es the mutation 
pattern for PD166326, an alternative Abl kinase inhibitor. Blood, 
105:1652–9.
Wang Y, Cai D, Brendel C, et al. 2007. Adaptive secretion of granulocyte-
macrophage colony-stimulating factor (GM-CSF) mediates imatinib 
and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 
pathway activation. Blood, 109:2147–55.
Weisberg E, Grifﬁ  n JD. 2001. Mechanisms of resistance imatinib (STI571) 
in preclinical models and in leukemia patients. Drug Resist Updat, 
4:22–8.
Weisberg E, Manley P, Mestan J, et al. 2006. AMN107 (nilotinib): a novel 
and selective inhibitor of BCR-ABL. Br J Cancer, 94:1765–9.
Weisberg E, Manley PW, Breitenstein W, et al. 2005. Characterization of 
AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer 
Cell, 7:129–41.
Weisberg E, Manley P, Cowan-Jacob SW, et al. 2007. Second generation 
inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic 
myeloid leukaemia. Nature Reviews Cancer, 7:345–56.
Weisdorf DJ, Anasetti C, Antin JH, et al. 2002. Allogeneic bone mar-
row transplantation for chronic myelogenous leukemia:comparative 
analysis of unrelated versus matched sibling donor transplantation. 
Blood, 99:1971–77.
Weisser M, Schleuning M, Haferlach C, et al. 2007. Allogeneic stem-cell 
transplantation provides excellent results in advanced stage chronic 
myeloid leukemia with major cytogenetic response to pre-transplant 
imatinib therapy. Leuk Lymphoma, 48:195–201.
Wetzler M, Kantarjian H, Kurzrock R, et al. 1995. Interferon-alpha therapy 
for chronic myelogenous leukemia. Am J Med, 99:402–11.
Wilkinson GR. 2005. Drug metabolism and variability among patients in 
drug response. N Engl J Med, 352:2211–21.
Willis SG, Lange T, Demehri S, et al. 2005. High-sensitivity detection of 
BCR-ABL kinase domain mutations in imatinib-naive patients:cor-
relation with clonal cytogenetic evolution but not response to therapy. 
Blood, 106:2128–37.
Wohlbold L, van der Kuip H, Miething C, et al. 2003. Inhibition of bcr-
abl gene expression by small interfering RNA sensitizes for imatinib 
mesylate (STI571). Blood, 102:2236–9.
Xie S, Lin H, Sun T, et al. 2002. Jak2 is involved in c-Myc induction by 
Bcr-Abl. Oncogene, 21:7137–46.
Xie S, Wang Y, Liu J, et al. 2001. Involvement of Jak2 tyrosine phosphor-
ylation in Bcr-Abl transformation. Oncogene, 20:6188–95.
Yokota A, Kimura S, Masuda S, et al. 2007. INNO-406, a noval Bcr-Abl/Lyn 
dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia 
cells in the central nervous system, and cyclosporine A augments its 
in vivo action. Blood, 109:306–14.
Young MA, Shah NP, Chao LH, et al. 2006. Structure of the kinase domain 
of an imatinib-resistant Abl mutant in complex with the Aurora kinase 
inhibitor VX-680. Cancer Res, 66:1007–14.
Zaucha JM, Prejzner W, Giebel S, et al. 2005. Imatinib therapy prior to mye-
loablative allogeneic SCT. Bone Marrow Transplant, 36:417–24.
Zion M, Ben-Yehuda D, Avraham A, et al. 1994. Progressive de novo DNA 
methylation at the bcr-abl locus in the course of chronic myelogenous 
leukemia. Proc Natl Acad Sci USA, 91:10722–6.
Zonder JA, Pemberton P, Brandt H, et al. 2003. The effect of dose increase of 
imatinib mesylate in patients with chronic or accelerated phase chronic 
myelogenous leukemia with inadequate hematologic or cytogenetic 
response to initial treatment. Clin Cancer Res, 9:2092–7.